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ABSTRACT 
 
 
 The present research work Cefixime Controlled Gas Powered System (CGPS) 
are retained for longer period oftime in the stomach. The bioavailability of cefixime is 
around 40-50 %. The gas powered tablets of Cefixime were prepared by direct 
compression method. The formulations were evaluated for quality control tests and all 
the physical parameters evaluated are within the acceptable limits. Drug compatibility 
with excipients was Checkedby FTIR studies and these results were revealed that, no 
interaction between drug with the excipients used. The results of in-vitro buoyancy 
time and lag time study revealed that as the concentration of sodium bicarbonate 
increases there is increase in total buoyancy time and decrease in lag time. In all the 
formulations buoyancy time ranges from 40-690 min and lag time ranges from 65-10 
min. The formulation F3 shows the lag time of 10 min. and buoyancy time 600 min. 
The release of cefixime from all the formulations was in the range of 46.67- 58.93 % 
at the end of 6 hrs. and 64.43-98.49 % at the end of 24 hrs. The CGPS system using 
sodium carboxy methyl cellulose along with sodium bicarbonate and citric acid added 
significantly increased the drug release from the formulation. It is also evident that 
sodium bicarbonate levels had a considerable effect on the drug release profile. The 
stability study conducted as per the ICH guidelines and the formulations were found 
to be stable. From this study, it can be concluded that, the formulation retained for 
longer periods of time in the stomach and provides controlled release of the drug. 
Hence, improve the therapeutic effect of the drug. 
 
Keywords: Cefixime, Lactose, Hpmc, Carbopol, Eudragit, Sodium bicarbonate, Citric 
acid, Mg.sterate, Talc. 
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INTRODUCTION 
 Oral drug delivery is the most widely utilized route of administration among all 
the routes that have been explored for systemic delivery of drugs via pharmaceutical 
products of different dosage form. Oral route is considered most natural, uncomplicated, 
convenient and safe due to its ease of administration, patient acceptance, and cost-
effective manufacturing process1. All the pharmaceutical products formulated for 
systemic delivery via the oral route of administration, irrespective of the mode of delivery 
(immediate, sustained or controlled release) and the design of dosage form (solid 
dispersion or liquid), must be developed within the intrinsic characteristics of GI 
physiology. Therefore the scientific framework required for the successful development 
of oral drug delivery systems consists of basic understanding of (i) Physicochemical, 
pharmacokinetic and pharmacodynamic characteristics of the drug (ii) the anatomic and 
physiologic characteristics of the gastrointestinal tract and (iii) physicochemical 
characteristics and the drug delivery mode of the dosage form to be designed. 
Conventional oral controlled dosage forms suffer from mainly two adversities2. The short 
gastric retention time (GRT) and unpredictable gastric emptying time (GET). A relatively 
brief GI transit time of most drug products impedes the formulation of single daily dosage 
forms.  
Altering the gastric emptying can overwhelm these problems. Therefore it is 
desirable, to formulate a controlled release dosage form that gives an extended GI 
residence time. 
 One of the most feasible approaches for achieving a prolonged and predictable 
drug delivery profiles in gastrointestinal tract is to control the gastric residence time 
(GRT) using gastro retentive dosage forms (GRDFs) that offer a new and better option for 
drug therapy3.  
 Dosage forms that can be retained in stomach are called gastro retentive drug 
delivery systems (GRDDS). GRDDS can improve the controlled delivery of drugs that 
have an absorption window by continuously releasing the drug for a prolonged period of 
time before it reaches its absorption site thus ensuring its optimal bioavailability2.                        
 During the last decade many studies have been performed concerning the sustained 
release dosage form of drugs, which have aimed at the prolongation of gastric emptying 
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time (GET)  The GET has been reported to be from 2 to 6 hours in humans in the fed 
state. Accordingly orally, sufficient bio availability and prolongation of the effective 
plasma level occasionally cannot be obtained. 
            Controlled release drug delivery systems that can be retained in stomach for a 
long time are important for drug that are degraded in intestine or for drugs like antacids or 
certain enzymes that should act locally in 
intestine due to alkaline pH, gastric retention may increase solubility before they are 
emptied, resulting in improved gastrointestinal absorption of drugs with narrow 
absorption window as well as for control
absorption limitation4.  
GASTRORETENTIVE DOSAGE FORMS AN OVERVIEW
Gastroretentive Dosage Form (GRDF)
Dosage forms that can be retained in stomach are called 
deliverysystems (GRDDS).GRDDS can improve the controlled delivery of drugs that 
have an absorption window by continuously releasing the drug for a prolonged period of 
time before it reaches its absorption site thus ensuring its optimal 
Physiological Considerations
Stomach: The Site for Gastro Retention 
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The stomach is situated in the left upper part of the abdominal cavity immediately 
under the diaphragm. Its size varies according to the amount of distension, up to 1500 ml 
following a meal; after food has emptied, a collapsed state is obtained with resting 
volume of 25-50 ml. The stomach is anatomically divided into 3 parts, fundus, body and 
antrum (or pylorus). The proximal stomach, made up of fundus and body regions serves 
as a reservoir for ingested materials while the distal region (antrum) is the major site of 
mixing motions, acting as a pump to accomplish gastric emptying.  
Gastrointestinal Motility & Emptying Of Food  
  The process of gastric emptying occurs both during fasting and fed states, 
however the pattern of motility differs markedly in the two states. Two distinct patterns of 
gastrointestinal motility and secretion exist corresponding to the fasted and fed states. As 
a result the bioavailability of orally administered drugs will vary depending on the state of 
feeding.  
In the fasted state, it is characterized by an interdigestive series of electrical event 
and cycle, both through the stomach and small intestine every 2-3 hrs. This activity is 
called the interdigestive myoelectric cycle or Migrating motor complex (MMC) is often 
divided into four consecutive phases: basal (Phase I) pre burst (Phase II), burst (Phase 
III), and Phase IV intervals. 
PHASE I the quiescent period, lasts from 30 to 60 mins and is characterized by a 
lack of secretary, electrical and contractile activity. PHASE II , exhibits intermittent 
activity for 20-40 min, during which the contractile motions increase in frequency and 
size. Bile enters the duodenum during this phase, whereas gastric mucus discharge occurs 
during the latter part of phase II and throughout phase III. PHASE III is a short period of 
intense large regular contractions, termed “housekeeper waves” that sweep off undigested 
food and last 10-20 min. PHASE IV is the transition period of 0-5 mins between Phase 
III & I.  
The motor activity in the fed state is induced 5-10 mins after ingestion of a meal 
and persists as long as food remains in the stomach. The larger the amount of food 
ingested, the longer the period of fed activity, with usual time spans of 2-6 h, and more 
typically, 3-4 h, with phasic contractions similar to Phase II of MMC. 
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 When CRDDS are administered in the fasted state, the MMC may be in any of its 
phases, which can significantly influence the total gastric residence time (GRT) and 
transit time in gastrointestinal tract.  
         This assumes even more significance for drugs that have an absorption window 
because it will affect the amount of time the dosage form spends in the region preceding 
and around the window. The less time spent in that region, the lower the degree of 
absorption. On the other hand, in the fed stomach the gastric retention time (GRT) of non 
disintegrating dosage forms depends mostly on their size and composition and caloric 
value of food.  
Requirements for Gastro Retention  
From the discussion of the physiological factors in stomach, to achieve gastro 
retention, the dosage form must satisfy some requirements. One of the key issues is that 
the dosage form must be able to withstand the forces caused by peristaltic waves in the 
stomach and constant grinding and churning mechanisms. It must resist premature gastric 
emptying and once the purpose has been served, it should be removed from the stomach 
with ease. 
Approaches to Gastric Retention  
Over the last 3 decades, various approaches have been pursued to increase the 
retention of an oral dosage form in the stomach. These systems include: Bioadhesive 
systems, swelling and expanding systems, High density systems, Floating systems, 
Modified systems.                   Fig: 1       
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 Incorporation of passage delaying food excipients, principally fatty acids, to 
decrease the gastric emptying rate.  
 Bio adhesive research based upon the adhesive capacity of some polymer with 
glycoprotein (Mucin) closely applied to the surface epithelium of the stomach and 
intestine.  
The other approach is to alter the formulation's density by using either high or 
low-density pellets, so called altered density approach.  
High density approach 
Here, the density of the pellets must exceed that of normal stomach and should be 
at least 1.40. In preparing such formulations, drug can be coated on a heavy core or mixed 
with heavy, inert materials such as barium sulfate, titanium dioxide, iron powder and 
oxide. The weighed pellet can then be covered with a diffusion controlled membrane.  
 
Low-density approach 
While the system is floating on the gastric contents the drug is slowly released 
from the low density pellets or floating drug delivery systems (FDDS) and are also 
called as hydro dynamically balanced systems (HBS). FDDS or HBS have a bulk 
density lower than gastric fluid, that is, bulk density of less than one. HBS 
remains buoyant in the stomach without affecting the gastric emptying rate for 
a prolonged period of time and the drug is released slowly at a desired rate 
from the system. After the release of the drug, the residual system is emptied 
from the stomach.  
         Shells of polymer with lower density than that of the gastrointestinal fluid, (ex 
polystyrene) have been used for this purpose. Swelling type dosage forms are 
such that on swallowing these products swell to an extent that prevents their 
exit from the stomach through the pylorus. As a result, the dosage form is 
retained in the stomach for a long period of time. These systems may be 
referred as 'plug type system' since they exhibit tendency to remain logged at 
the pyloric sphincter. Modified shape systems are no disintegrating geometric 
shapes molded from silstic elastomer or extruded from polyethylene blends which 
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extend the gastric retention time depending on size, shape and flexural modulus 
of the drug delivery system.  
      Unfortunately, most of these systems have many drawbacks. Floating system requires 
presence of food to delay their gastric emptying. They do not always release  the drug at 
the intended sit. Bio-adhesive system adheres to the mucus. This adhesion is a result of 
electrostatic and H-bond formation at the mucus-polymer boundary. The 
bond formation is prevented by acidic environment and thick mucus present in 
the stomach.  
Different Techniques in Gastric Retention6, 7. 
A number of approaches have been used to increase the GRT of a dosage form in 
stomach by employing a variety of concepts. These include – 
 
Buoyant/ Floating Systems: 
Floating Drug Delivery Systems8 (FDDS) have a bulk density lower than 
gastric fluids and thus remain buoyant in the stomach for a prolonged period of time, 
without affecting the gastric emptying rate. While the system is floating on the gastric 
contents, the drug is released slowly at a desired rate from the system.  
After the release of the drug, the residual system is emptied from the 
stomach. This results in an increase in the GRT and a better control of fluctuations in the 
plasma drug concentrations. Floating systems can be classified into two distinct 
categories, non-effervescent and effervescent system. 
 
Graphic of Buoyant tablet, which is less dense than the stomach fluid 
therefore it remains in  the fundus. 
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Bio/Muco-adhesive Systems9, 10 
Bioadhesive drug delivery systems (BDDS) are used to localise a delivery device 
within the lumen to enhance the drug absorption in a site-specific manner. This approach 
involves the use of bioadhesive polymers, which can adhere to the epithelial surface in 
the stomach. A microbalance-based system is reported for measuring the forces of 
interaction between the GI mucosa and the individual polymers, and the Cahn Dynamic 
Contact Angle Analyzer has been used to study the adherence.5 Gastric mucoadhesion 
does not tend to be strong enough to impart to dosage forms the ability to resist the strong 
propulsion forces of the stomach wall. The continuous production of mucous by the 
gastric mucosa to replace the mucous that is lost through peristaltic contractions and the 
dilution of the stomach content also seems to limit the potential of mucoadhesion as a 
gastro retentive force. Some of the most promising excipients that have been used 
commonly in these systems include polycarbophil, carbopol, lectins, chitosan, CMC and 
gliadin, etc. Some investigators have tried out a synergistic approach between floating 
and bioadhesion systems. Other approaches reported include use of a novel adhesive 
material derived from the fimbriae (especially Type 1) of bacteria or synthetic analogues 
combined with a drug to provide for attachment to the gut, thereby prolonging the transit 
time, a composition comprising an active ingredient and a material that acts as a 
viscogenic agent (for example curdlan and/or a low-substituted hydroxypropylcellulose), 
etc.  
Swelling and Expanding Systems11: 
 Theseare the dosage forms, which after swallowing; swell to an extent that 
prevents their exit from the pylorus. As a result, the dosage form is retained in the 
stomach for a long period of time. These systems may be named as “plug type system”, 
since they exhibit the tendency to remain logged at the pyloric sphincter if that exceed a 
diameter of approximately 12-18 mm in their expanded state. The formulation is designed 
for gastric retention and controlled delivery of the drug into the gastric cavity. A balance 
between the extent and duration of swelling is maintained by the degree of cross-linking 
between the polymeric chains. A high degree of cross-linking retards the swelling ability 
of the system maintaining its physical integrity for prolonged period. 
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High Density Systems8: 
These systems with a density of about 3 g/cm3 are retained in the rugae of the 
stomach and are capable of withstanding its peristaltic movements. A density of 2.6-2.8 
g/cm3 acts as a threshold value after which such systems can be retained in the lower part 
of the stomach. High-density formulations include coated pellets. Coating is done by 
heavy inert material such as barium sulphate, zinc oxide, titanium dioxide, iron powder 
etc.  
Incorporation of Passage Delaying Food Agents12: 
Food excipients like fatty acids e.g. salts of myristic acid change and modify the 
pattern of the stomach to a fed state, thereby decreasing gastric emptying rate and 
permitting considerable prolongation of release. The delay in the gastric emptying after 
meals rich in fats is largely caused by saturated fatty acids with chain length of C10-C14. 
Ion Exchange Resin13: 
A coated ion exchange resin bead formulation has been shown to have gastric 
retentive properties, which was loaded with bicarbonates. Ion exchange resins are loaded 
with bicarbonate and a negatively charged drug is bound to the resin. The resultant beads 
were then encapsulated in a semi-permeable membrane to overcome the rapid loss of 
carbon dioxide. Upon arrival in the acidic environment of the stomach, an exchange of 
chloride and bicarbonate ions take place. As a result of this reaction carbon dioxide was 
released and trapped in the membrane thereby carrying beads towards the top of gastric 
content and producing a floating layer of resin beads in contrast to the uncoated beads, 
which will sink quickly. 
Osmotic Regulated Systems2: 
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a bio-erodible capsule. In the stomach the capsule quickly 
disintegrates to release the intra gastric osmotically controlled drug delivery device. The 
inflatable support inside forms a deformable hollow polymeric bag that contains a liquid 
that gasifies at body temperature to inflate the bag. The osmotic controlled drug delivery 
device consists of two components – drug reservoir compartment and osmotically active 
compartment. 
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Background for development of FDDS: 
Many therapeutic agents ate metabolized in the upper GI tract into an active form. 
This active form is then through the wall intestine. The therapeutic agents ate metabolized 
by enzymes in the upper GI tract. If the therapeutic agent is present in large quantities, 
saturation of these enzymes can occur with the result that most of the 
therapeutic agent passes through the GI tract therefore limits the potency of the 
therapeutic agent.  
Conventional controlled release dosage forms have a density greater than that of 
gastric contents, thus these dosage forms sink to the bottom of the stomach once ingested. 
The de novo design of oral controlled drug systems (DDS) is known in the art to achieve 
more predictable bioavailability of drugs.  However, it is well known that conventional 
release DDS do not Overcome adversities such as gastric residence time (GST) and 
gastric empty time (GET). Gastric emptying is the process by the fasted stomach exhibits 
a cyclic activity called the inter-digestive migrating motor complex (IMMC). The purpose 
of this cycle is to migrate the contents of the stomach through the pyloric sphincter 
although ingestion of food interrupts the cycle. 
         One approach to overcome the adversities of GRT and GET is the floating system 
also known as hydrodynamically balanced systems. These systems are expected to remain 
lastingly buoyant on the gastric contents without affecting the intrinsic rate of emptying 
because their bulk density is lower than that of the gastric fluids. The floating forms 
maintain their low density value while the polymer hydrates and forms a gel. The drug is 
progressively release from the swollen matrix in the case of conventional hydrophilic 
matrices. 
Types of Floating Drug Delivery Systems (FDDS) 10 
Floating drug delivery systems (FDDS) have a bulk density less than gastric fluids 
and so remain buoyant in the stomach without affecting the gastric emptying rate for a 
prolonged period of time. While the system is floating on the gastric contents the drug is 
released slowly at the desired rate from the system.  
After release of drug, the residual system is emptied from the stomach. This result 
in an increased GRT and a better control of the fluctuations in plasma drug concentration 
However, besides a minimal gastric content needed to allow the proper achievement of 
the buoyancy retention principle, a minimal level of floating force (F) is also required to 
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keep the dosage form reliably buoyant o
force kinetics, a novel apparatus for determination of resultant weight (RW) has been 
reported in the literature. The RW apparatus (fig: 4) operates by measuring continuously 
the force equivalent to F (as a function of time) that is required to maintain the submerged 
object. The object floats better if RW is on the higher positive side. This apparatus helps 
in optimizing FDDS with respect to stability and durability of floating forces produced in 
order to prevent the drawbacks of unforeseeable intragastric buoyancy capability 
variations. 
 
 
 
 
 
 
   Fig: 4. Diagrammatic representation of RW apparatus.              
Based on the mechanism of buoyancy, two distinctly different technologies have 
been utilized in development of FDDS, which are:
A. Effervescent System, and
B. Non- Effervescent System.
Effervescent System12, 14. 
Effervescent systems include use of gas generating agents, carbonates (ex. Sodium 
bicarbonate) and other organic acid (e.g. citric acid and tartaric acid) present in the 
formulation to produce carbon dioxide (CO
and making it float on the gastric fluid. An alternative is the incorporation of matrix 
containing portion of liquid, which produce gas that evaporates at body tempera
These effervescent systems further classified into two types.
 Gas Generating systems 
 Volatile Liquid/Vacuum Containing Systems.
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2) gas, thus reducing the density of the system 
 
 
 
RW or F = F buoyancy - F gravity 
                  = (Df- Ds) gV 
 Where  
RW = total vertical force 
Df= fluid density, 
Ds= object density, V = volume; 
 
Page 10 
 
ture. 
                                                                                           
 
Department of pharmaceutics, Cherraan’s College of Pharmacy, Coimbatore.
Gas – Generating Systems: 
Intra Gastric Single Layer Floating Tablets or Hydrodynamically Balanced 
System(HBS):  
These are as shown in Fig. 5 and formulated by intimately mixing the CO
generating agents and the drug with in the matrix tablet.   These have a bulk density lower 
than gastric fluids and therefore remain floating in the stomach unflattering the gastric 
emptying rate for a prolonged period. The drug is slowly released at a desired rate from 
the floating system and after the complete release the residual system is expelled from the 
stomach. This leads to an increase in the GRT and a better control over fluctuatio
plasma drug concentration.  
 
   
 
 
 
                                               
Fig:    Intra 
 Intra Gastric Bilayer Floating Tablets:
These are also compressed tablet as shown in Fig  6and containing two layer i.e., 
i. Immediate release layer and 
ii. Sustained release layer.
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Gastric Single Layer Floating systems. 
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Fig:   Intra
Multiple Unit type floating pills:
These systems consist of sustained release pills as ‘seeds’ surrounded by double 
layers (fig: 7). The inner layers consist of effervescent agents while the outer layer is of 
swellable membrane layer. When the system is immersed in dissoluti
temperature, it sinks at once and then forms swollen pills like balloons, which float as 
they have lower density. This lower density is due to generation and entrapment of CO
within the system.  
Fig:  15.A multi-unit oral buoyant 
(A) penetration of water; (B) generation of CO
drug. Key: (a) conventional SR pills; (b) effervescent layer; (c) swellable layer; 
(d) expanded swellable membrane layer; (e) surf
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 Gastric Bilayer Buoyant Tablet. 
 
on medium at body 
 
dosage system. Stages of floating mechanism: 
2 and floating; (C) dissolution of 
ace of water in the beaker (37
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II. Volatile Liquid / Vacuum Containing Systems
1. Intragastric Floating Gastrointestinal Drug Delivery System:
These systems can be made to float in the stomach because of floatation chamber, 
which may be a vacuum or 
encapsulated inside a microprous compartment, as shown in Fig.8
 
  
 
Fig:   Intra Gastric Floating Gastrointestinal Drug Delivery Device
 Inflatable Gastrointestinal Delivery Systems:
In these systems an inflatable chamber is incorporated, which contains liquid ether 
that gasifies at body temperature to cause the chamber to inflate in the stomach. These 
systems are fabricated by loading the inflatable chamber with a drug reservoir, which can 
be a drug, impregnated polymeric matrix, then encapsulated in a gelatin capsule. 
 
 
 
 
 
                           Fig no:   Inflatable
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filled with air or a harmless gas, while drug reservoir is 
 
 
 
 Gastrointestinal Delivery System 
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After oral administration, the capsule dissolves to release the drug reservoir 
together with the inflatable chamber. The inflatable chamber automatically inflates and 
retains the drug reservoir compartment in the stomach. The drug continuously released 
from the reservoir into the gastric fluid. This system is shown in Fig. 9
 IntragastricOsmotically Controlled Drug Delivery System:  
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach, the capsule quickly 
disintegrates to release the intragastircosmoti
inflatable support inside forms a deformable hollow polymeric bag that contains a liquid 
that gasifies at body temperature to inflate the bag. The osmotic pressure controlled drug 
delivery device consists of two c
osmotically active compartment.
The drug reservoir compartment is enclosed by a pressure responsive collapsible 
bag, which is impermeable to vapour and liquid and has a drug delivery orifice. The 
osmotically active compartment contains an osmotically active salt and is enclosed within 
a semi permeable housing. In the stomach, the water in the GI fluid is continuously 
absorbed through the semi permeable membrane into osmotically active compartment to 
dissolve the osmotically active salt. An osmotic pressure is thus created which acts on th
collapsible bag and in turn forces the drug reservoir compartment to reduce its volume 
and activate the drug reservoir compartment to reduce its volume and activate the drug 
release of a drug solution formulation through the delivery orifice. 
The floating support is also made to contain a bio
predetermined time to deflate the support. The deflated drug delivery system is then 
emptied from the stomach. This system is shown in Fig.10
 
   
  
 
Fig:    IntragastricOsmotically
Introduction     
 
 
 
cally controlled drug delivery device. The 
omponents; drug reservoir compartment and an 
 
 
-erodible plug that erodes after a 
 
 Controlled Drug Delivery System
 
Page 14 
e 
 
                                                                                           
 
Department of pharmaceutics, Cherraan’s College of Pharmacy, Coimbatore.
Non-Effervescent Systems17
This type of system, after swallowing, swells unrestrained via imbibition of 
gastric fluid to an extent that it prevents their exit from the stomach. These systems may 
be referred to as the ‘plug-type systems’ since they have a tendency to remain lodged near 
the pyloric sphincter. One of the formulation methods of such dosage forms involves the 
mixing of drug with a gel, which swells in contact with gastric fluid after oral 
administration and maintains a relative integrity of shape and a bulk density of less than 
one within the outer gelatinous barrier. The air trapped by the swollen polymer confers 
buoyancy to these dosage forms. 
Other approaches reported in the literature are hydro dynamically 
systems developed by Sheth and Tossounian, which contain a mixture of drug and 
hydrocolloids, sustained release capsules containing cellulose derivatives like starch and a 
higher fatty alcohol or fatty acid glyceride, bilayer compressed caps
flexible sheet-like medicament devices, hollow microspheres of acrylic resins, 
polystyrene floatable shells, single and multiple unit devices with floatation chambers and 
microporous compartments and buoyant controlled release powder for
 
  
 
 
 
 
Recent developments include use of superporous hydrogels that expand 
dramatically (hundreds of times their dehydrated form within a matter of seconds) when 
immersed in water. Oral drug delivery formulations 
rapidly in the stomach, causing medications to move more slowly from the stomach to the 
intestines and be absorbed more efficiently by the body.
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balanced (HBS) 
ules, multilayered 
mulations, etc.
Fig:    Swelling systems 
made from the gels would swell 
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Factors affecting gastric retention: 
These factors include density, size and shape of dosage form, concomitant intake 
of food and drug such as anti-cholinergic agents (e.g. Atropine, propantheline), 
opiates (e.g. Codeine) and prokinetic agents (e.g. Metoclopramide) and 
biological factors such as gender, posture, age, body mass index and disease 
state. (e.g. Diabetes).  
In order for a HBS dosage form to float in the stomach the density of the dosage 
form should be less than the gastric contents. However, the floating force 
kinetics of such dosage form has shown that the bulk density of a dosage form 
is not the most appropriate parameters for describing its buoyancy. 
These are better represented and monitored by resultant weight measurements and 
swelling experiments. This is because the magnitude of floating strength may 
vary as a function of time and usually decreases after immersion of the dosage 
form into fluid consequently to the evolution of its hydro-dynamical 
equilibrium.  
The prolongation of gastric residence time (GRT) by food is expected to 
maximize drug absorption form FDDS due to increased dissolution of drug and longer 
residence at the most favorable sites of absorption. GRT of a dosage form in 
the fed state can also be influenced by its size. 
Technological developments in FDDS (floating drug delivery system): 
Most of the floating systems reported in the literature are single unit systems, 
such as floating tablets. These systems are unreliable and irreproducible in 
prolonging residence time in the stomach when orally administered owing to 
their fortuitous (all-or-nothing) emptying process. On the other hand, multiple 
unit dose forms appear to be better suited since they are claimed to reduce the 
inter subject variability in absorption and lower the probability of 
dose-dumping. It also eliminates the dependence of the drug effect on gastric emptying, 
the mini depots being sufficiently small to make possible their passage through pylorus 
even between its actual openings. As a result, the drug will reach the site of 
optimum absorption and a high local concentration will also be avoided. 
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MARKETED PRODUCTS OF FDDS18 
Table:1 
Drugs explored for various floating dosage forms 
SL.NO 
BRAND 
NAME 
DRUG (DOSE) COMPANY 
COUNTRY 
TECHNOLOGY 
1. Modapar® Levodopa(100mg), 
Benserazide(25mg) 
Roche Products, 
USA 
Floating CR capsule 
2. Valrelease® Diazepam (15 mg) Hoffmann-
LaRoche, USA 
Floating capsule 
3. Liquid 
Gavison® 
Alhydroxide(95mg), 
Mg carbonate (358 
mg) 
GlaxoSmithKline, 
India 
Effervescent floating 
liquid alginate 
Preparation 
4. Topalkan® Al-Mg antacid Pierre Fabre 
Drug, France 
Floating liquid alginate 
preparation 
5. Conviron Ferrous sulphate Ranbaxy, India Colloidal gel forming 
FDDS 
6. Cifran OD® Ciprofloxacin(1 gm) Ranbaxy, India Gas-generating floating 
tablet 
7. Cytotec® Misoprostal (100 
mcg/200 mcg) 
Pharmacia, USA Bilayer floating capsule 
8. Oflin OD® Ofloxacin (400mg) Ranbaxy, India Gas generating floating 
tablet 
9 Glumetza™ Metformin HCl Depomed,usa Acuform™ 
10 ProQuin® 
XR 
Ciprofloxacin 
hydrochloride 
Depomed,usa Acuform™ 
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Table: 18 
Dosage 
Forms 
Drugs 
Microspheres  Aspirin, Ibuprofen, Tranilast 
Granules  Diclofenac sodium, Indomethacin, Prednisolone  
Capsules  Diazepam, Furosemide, L-Dopa and Benserazide  
Tablets / pills  AmoxycillinTrihydrate, Ampicillin, Diltiazem, p -Aminobenzoic acid, 
Riboflavin-5’-phosphate, Theophylline, Verapamil HCl 
 
ADVANTAGES OF FDDS2: 
Floating dosage systems form important technological drug delivery systems with gastric 
retentive behavior and offer several advantages in drug delivery. These advantages 
include:  
1. Improved drug absorption, because of increased GRT and more time spent by the 
dosage form at its absorption site.  
2. Controlled delivery of drugs. 
3. Delivery of drugs for local action in the stomach.  
4. Minimizing the mucosal irritation due to drugs, by drug releasing slowly at   
controlled rate.  
5. Treatment of gastrointestinal disorders such as gastro-esophageal reflux.  
6. Simple and conventional equipment for manufacture.  
7. Ease of administration and better patient compliance. 
 
 
 
Other advantages are: 
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Sustained drug delivery:  
        As mentioned earlier, drug absorption from oral controlled release (CR) dosage 
forms is often limited by the short GRT available for absorption.  
However, HBS type dosage forms can retain in the stomach for several hours and 
therefore, significantly prolong the GRT of numerous drugs. .  
These special dosage forms are light, relatively large in size, and do not easily 
pass through pylorus, which has an opening of approx. 0.1– 1.9 cms.  
Site specific drug delivery  
A floating dosage form is a feasible approach especially for drugs which have 
limited absorption sites in upper small intestine.  
The controlled, slow delivery of drug to the stomach provides sufficient local 
therapeutic levels and limits the systemic exposure to the drug. This reduces side effects 
that are caused by the drug in the blood circulation. In addition the prolonged gastric 
availability from a site directed delivery system may also reduce the dosing frequency.  
The eradication of Helicobacter pylorirequires the administration of various 
medicaments several times a day, which often results in poor patient compliance. More 
reliable therapy can be achieved by using GRDDS. Floating alginate beads have been 
used for the sustained release of Amoxycillintrihydrate.  Thus, it can be expected that the 
topical delivery of antibiotic through a FDDS may result in complete removal of the 
organisms in the fundal area due to bactericidal drug levels being reached in this area, and 
might lead to better treatment of peptic ulcer.   
Pharmacokinetic advantages  
As sustained release systems, floating dosage forms offer various potential 
advantages. Drugs that have poor bioavailability because their absorption is limited to 
upper GI tract can be delivered efficiently thereby maximizing their absorption and 
improving their absolute bioavalabilities.  
Floating dosage forms with SR characteristics can also be expected to reduce the 
variability in transit performance. In addition, it might provide a beneficial strategy for 
gastric and duodenal cancer treatment.  
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The concept of FDDS has also been utilized in the development of various anti- 
reflux formulations. Floating systems are particularly useful for acid soluble drugs, drugs 
poorly soluble or unstable in intestinal fluids, and those which may undergo abrupt 
changes in their pH dependent solubility due to food, age and disease states.  
LIMITATIONS  
1. The major disadvantage of floating system is requirement of a sufficient high level 
of fluids in the stomach for the drug delivery to float. However this limitation can 
be overcome by coating the dosage form with the help of bioadhesive polymers 
that easily adhere to the mucosal lining of the stomach. 
2. Floating system is not feasible for those drugs that have solubility or stability 
problem in gastric fluids. 
3. The dosage form should be administered with a minimum of glass full of water 
(200-250 ml). 
4. The drugs, which are absorbed throughout gastro-intestinal tract, which under 
gofirstpass metabolism (nifedipine, propranolol etc.),are not desirable candidate. 
5.  Some drugs present in the floating system causes irritation to gastric mucosa. 
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Antibiotics 
The word “antibiotics” comes from the Greek anti (“against”) and bios 
(“life”).Antibiotics are drugs that either destroy bacteria or prevent their reproduction. 
Antibiotics that kill bacteria are called “bactericidal” and the ones that stop the growth of 
bacteria are called “bacteriostatic”. 
Since penicillin’s introduction during the 1940s, scientists developed numerous other 
antibiotics. Today, over 100 different antibiotics are available. About 90% of antibiotics 
are made from living organisms search as bacteria, others produced synthetically, and 
either in whole or in park. 
Antibiotics classification 
Although there are several classification schemes for antibiotics, based on bacterial 
spectrum (broad,  narrow ) or administration (injectable, oral, topical), or type of activity 
(bactericidal, bacteriostatic). Most commonly used types of antibiotics are: Penicillin’s, 
Fluoroquinolones, Cephalosporin’s, Macrolides, and Tetracycline’s. 
Penicillins 
The penicillin’s are the oldest class of antibiotics. Penicillins have a common chemical 
structure which they share with the cephalosporins; penicillins are generally bactericidal, 
inhibiting formation of the cell wall. 
There are four types of penicillins: 
• The natural penicillins are based on the original penicillin-G structure.Penicillin-G 
types are effective against gram-positive strains of streptococci, staphylococci, 
and some gram-negative bacteria such as meningococcus. 
• Penicillinase-resistant penicillins are active even in the presence of the bacterial 
enzyme that in actives most natural penicillins. 
• Extended spectrum pencillins which are effective against a wider range of 
bacteria. 
• Aminopenicillins such as ampicillin and amoxicillin have an extended spectrum of 
action compared with the natural penicillins. 
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Penicillins side effects 
1. Penicillines are among the least toxic drugs known. The most common side effect 
of penicillin is diarrhea.Nausea, vomiting, and upset stomachs are also common. 
In rare cases penicillins can cause immediate and delayed allergic reaction – 
specifically, skin rashes, fever, and anaphylactic shock. Penicillins are classed as 
category B during pregnancy. 
 
Cephalosporins: 
 Cephalosporins   have a mechanism of action identical to that of the penicillins. 
However, the basic chemical structure of the penicillins and cephalosporins differs in 
order respects, resulting in some difference in the spectrum of antibacterial activity. 
 The first generation cephalosporins include: cephalothin, cefazolin, cefadroxil. 
Their spectrums of activity are quite similar. They possess generally excellent coverage 
against most gram-positive pathogens and variable to poor coverage against most gram 
negative pathogens. 
 The second generation cephalosporins include: cefaclor, ceforanide,cefuroxime. In 
addition to the gram-positive spectrum of the first generation cephalosporins, these agents 
have expanded gram-negative spectrum. 
 The third generation cephalosporins have much expanded gram-negative activity. 
However, some members of this group have decreased activity against gram-positive 
organism. The third generation cephalosporins include: cefdaloxime. 
 The fourth generation cephalosporins are extended-spectrum agents with similar 
activity against gram-positive organism as first-generation cephalosporins. Many fourth 
generation cephalosporins can cross blood brain barrier and are effective in meningitis. 
The fourth generation cephalosporin include: cefclidine, cefpirome, cefquinome. 
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Classification of Cephalosporins  
 Cephalosporins are grouped into “generation” based on their spectrum of 
antimicrobial activity. The first cephalosporins were designed first generation while later, 
more extended spectrum cephalosporins were classified as second generation 
cephalosporins. Each newer generation of cephalosporins has significantly greater gram-
negative antimicrobial properties than the preceding generation, in most cases with 
decreased activity against gram-positive organisms. Fourth generation cephalosporins, 
however, have true broad spectrum activity 
First generation: 
 First generation cephalosoporins are moderate spectrum agents. They are effective 
alternatives for treating staphylococcal and streptococcal infections and therefore are 
alternatives for skin and soft-issues infections, as well as for streptococcal pharyngitis 
 
The first generation cephalosporins are: 
 
• Cefadroxil 
• Cephalexin 
• Cephaloridine 
• Cephalothin 
 Cefazolin is the most commonly used first generation cephalosporin. The other 
first generation cephalosporins have similar efficacy to cephalexin, but must be dosed 
more often, and are therefore not as commonly prescribed. 
Second generation: 
  The second generation cephalosporins have a greater gram-negative spectrum 
while retaining some activity gram-positive bacteria. They are also more to beta-
lactamase. They are useful agents for treating upper and lower respiratory tract infections.  
Cefoxitin is a second generation cephalosporin with anaerobic activity. 
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The second generation cephalosporins are: 
 
• Cefaclor 
• Cefprozil 
• Cefuroxime 
Third generation: 
 Third generation cephalosporins have a broad spectrum of activity and further 
increased activity against gram-negative organisms. Some members of this group have 
decreased activity against gram-positive organisms. The parenteral third generation 
cephalosporins have excellent activity against most strains of streptococcus pneumonia, 
including the vast majority of those with intermediate and high level resistance to 
penicillin. 
The third generation cephalosporins are: 
 
• Cefixime 
• Cefpodoxime 
• Ceftriaxone 
Fourth generation: 
 Fourth generation cephalosporins are extended spectrum agents with similar 
activity against gram-positive organisms as first cephalosporins. They also have a greater 
resistance to beta-lactamases than the third generation cephalosporins. Many can cross 
blood brain barrier and are effective in meningitis. 
 
The fourth generation cephalosporins are: 
 
• Cefepime 
• Cefozopran 
• Cefquinome 
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Cephalosporin side effects: 
 Cephalosporin generally causes few side effects .common side effects associated 
these drugs include: diarrhoea, nausea, mild stomach cramps or upset. Cephalosporins 
antibiotics are contraindicated in people with a history of allergic reactions to penicillins 
or cephalosporins. Cephalosporins antibiotics are classed as pregnancy category B. 
Administration 
 Oral antibiotics are simply ingested, while intravenous antibiotics are used in 
more serious cases, such as deep-seated systemic infections. Antibiotics may also 
sometimes be administered   topically, as with eye drops or ointments. 
Side effects 
 There are various side-effects that can be very serious depending on the antibiotics 
used and the microbial organisms targeted. The safety profiles of newer medications may 
not be as well established   as those that have been in use for many years. Adverse effects 
can range from fever and nausea to major allergic reactions including  photo dermatitis 
One of the more common side-effects is diarrhea is sometimes caused by anaerobic 
bacterium  clostridium difficile.  Such overgrowth of pathogenic bacteria may be 
alleviated by ingesting probiotics during a course of antibiotics. It has been hypothesized 
that interference of some antibiotics with the efficiency of birth control pills is thought 
occur in two ways.  Modification of the internal flora may result in reduced Absorption of 
oestrogens.  Second, induction of hepatic liver enzymes causing them metabolize the 
pill’s active ingredients faster may affect the pill’s usefulness. However, the majority of 
studies indicate that antibiotics do not interfere with contraception.  Even though a small 
percentage of women may experience decreased effectiveness of birth control pills while 
taking antibiotic, the failure rate is comparable to the failure rate of those taking the pill. 
Specific effects 
 Other effects of alcohol involve the activity of liver enzymes, which break down 
the antibiotics. In addition, serum levels of doxycycline and erythromycin in certain 
circumstances be significantly reduced by alcohol consumption. This is particularly 
important, since these drugs are bacteriostatic and require a sustained level of the drug in 
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the body to be effective: increased metabolism and clearance would result in diminished 
pharmacotherapeutic effect. 
4.3 Antibiotic resistance 
 The emergence of antibiotic resistance is in evolutionary process that is based on 
selection for organisms that have enhanced ability to survive doses of antibiotics that 
would have previously been lethal. Antibiotics like penicillin and erythromycin, which 
used to be one-time miracle cures, are now less effective because bacteria have become 
more resistant. Antibiotics themself act as a selective pressure that allows the growth of 
resistant bacteria within a population and inhibits susceptible bacteria. Antibiotic 
selection of pre-existing antibiotic resistant mutants within bacterial populations was 
demonstrated in 1943 by the Luria-Delbruck experiment. Survival of bacteria often 
results from an inheritable resistance. 
 The bacterial chromosome may fail to encode a protein that the antibiotic targets. 
Acquired resistance results from a mutation in the bacterial chromosome or the 
acquisition of extra –chromosomal DNA.  Antibiotic-producing bacteria have evolved 
resistance mechanisms that have been shown to be similar to, and may have been 
transferred to, antibiotic resistance strains. The spread of antibiotic resistance mechanisms 
occurs through vertical transmission of inherited mutations from previous generations and 
genetic recombination of DNA by horizontal genetic exchange. Antibiotic resistance is 
exchanged between different bacteria by plasmids that carry genes that encode antibiotic 
resistance that may result in co-resistance to multiple antibiotics. These plasmids can 
carry different genes with diverse resistance mechanisms to unrelated antibiotics but 
because they are located on the same plasmid multiple antibiotic resistances to the more 
than one antibiotic is transferred. 
Antibiotic misuse  
 The poster from the U.S. centres for Disease control and prevention   “get smart” 
campaign, intended for use in doctor’s offices and other health care facilities, warns that 
antibiotics do not work for viral illnesses such as the common cold. 
Inappropriate antibiotic treatment and overuse of antibiotics have been contributing factor 
the emergence of resistant bacteria. The problem is further exacerbated by self- 
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prescribing of antibiotics by individuals without be guide lines of a qualified clinician and 
non- therapeutics use of antibiotics as growth promoters in agriculture. Antibiotics are 
frequently prescribed for indications in which their use is not warranted, an incorrect or 
sub- optimal antibiotic is prescribed or in some cases for infections like to resolve without 
treatment. 
 Several organization concerned with antimicrobial resistance are lobbying to 
improve the regulatory climate. Approaches to tackling the issue of misuse and overuse of 
antibiotics by the establishment of the U.S. interagency Task Force on microbial 
resistance, are being organised and coordinated by the uscentres for disease control and 
prevention, the food and drug administration (FDA), and the national institutes of health 
(NIH), as well as federal agencies. 
 In agriculture, associated antibiotic resistance with the non-therapeutic use of 
antibiotics as growth promoters in animals resulted in their restricted use in the uk in the 
1970(swnn report 1969).at the current time there is a EU wide ban on the non-therapeutic 
use of antibiotics as growth promoters. It is estimated that greater than 70% of the 
antibiotics used in us are given to feed animals (example: chickens, pigs, and cattle) in the 
absence of disease. 
RESISTENCE-MODIFYING AGENTS 
 One solution to combat resistance currently being research is the development of 
pharmaceutical compounds that would revert multiple antibiotic resistances  
PHAGE THERAPY     
 The therapy was in use during the 1920s and 1930s on humans in the US. The 
success of these therapies largely rigorous scientific studies in the form of clinical trials 
commonly used to evaluated the efficacy of new medications on the efficacy of phage 
therapy are limited the original publications in to phage therapies are also generally in 
accessible. 
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BACTERIOCINS 
 Different classes of bacteriocins have different potentials as therapeutic agents. 
Small molecule bacteriocins (microcins, for example, and antibiotics) may be similar to 
the classic antibiotics; colicin-like bacteriocins are more likely to be narrow spectrum, 
demanding new molecular diagnostics prior to therapie but also not raising the spectre of 
resistance to the same degree.one draw back to the large –molecule antibiotics is that they 
have relative difficulty crossing membranes and travelling systemically throughout the 
body. For this reason, they are most often proposed for applications topically are gastro 
intestinally. 
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4. LITERATURE REVIEW 
 
Recent Reports on the Floating Drug Delivery System 
 
Abubakr O. Nuret al16 (2000) preparedCaptopril Floating and/or Bioadhesive 
Tablets by using two viscosity grades of hydroxypropylmethylcellulose (HPMC 4000 and 
15000 cps) and Carbopol 934P. In- vitro dissolution was carried out in simulated gastric 
fluid (enzyme free) at 37°C ± 0.1°C using the USP apparatus 2 basket method.  
  
Baumgartneret al19 (2000) developed floating matrix tablets by using 
HPMC,drug and different additives which after oral administration are designed to 
prolong the gastric residence time, increase the drug bioavailability and diminish the side 
effects of irritating drugs. The importance of the composition optimization, the 
technological process development for the preparation of the floating tablets with a high 
dose of freely soluble drug and characterization of those tablets (crushing force, floating 
properties in-vitro and in-vivo, drug release) was examined. The investigation shows that 
tablet composition and mechanical strength have the greatest influence on the floating 
properties and drug release.  
GuojieXuet al20 (2001) formulated floating tablets containing sodium bicarbonate 
and HPMC in a cetyl alcohol matrix. When hydrated in an acid medium, this tablet 
consisted of a mixed solid with a viscous surface layer containing carbon dioxide bubbles 
through which the active ingredient (FITC-dextran) was released into the aqueous 
environment. However, it was observed that, above a critical molecular weight, the FITC-
dextrn was only released into the medium by an erosion-type mechanism, whereas, below 
this value, both diffusion and erosion processes took place. 
A.H El-Kamelet al, (2001)21 prepared ketoprofen-floating oral deliver system 
which was prepared by emulsion–solvent diffusion technique.four different ratios of 
Eudragit s100 with Eudragit RL were used for floating microparticles.  
 
 Shoufeng Liet al (2003)22 investigated the effect of formulation variables on drug 
release and floating properties of floating delivery system of Calcium by using HPMC of 
different viscosity grades and Carbopol 934 P employing 23 full factorial designs. They 
observed that the decrease in release rate with an increase in viscosity of the polymeric 
system. 
                                                                                      Literature review 
 
Department of pharmaceutics, Cherraan’s College of Pharmacy, Coimbatore. 30 
 
  
Brijesh S. Daveet al, (2004)23 describedGastroretentive Drug Delivery System of 
Ranitidine Hydrochloride. InThis study discusses the preparation of gastroretentive 
tablets of Ranitidine HCl. The effervescent-based floating drug delivery was a promising 
approach to achieve in- vitro buoyancy. The addition of gel-forming polymer HPMC K4 
M and gas-generating agent sodium bicarbonate was essential to achieve in- vitro 
buoyancy. 
  
Mahesh Chavanpatilet al(2005)24 developed sustained release gastroretentive 
drug delivery system for ofloxacin. The design of the delivery system was done by, 
HPMC K100M, crospovidone and its combinations were tried in order to get the desired 
sustained release profile over a period of 24 h. Various formulations were evaluated for 
buoyancy lag time, duration of buoyancy, dimensional stability, drug content and in- vitro 
drug release profile. It was found that dimensional stability of the formulation increases 
with the increasing psyllium husk concentration. It was also found that in- vitro drug 
release rate increased with increasing amount of crospovidone due to the increased water 
uptake, and hence increased driving force for drug release 
 
XiaoqiangXuet al (2006)25 developed a sustained release tablets of 
PhenoporlamineHCl by using HPMC K4M and Carbopol    971 P. They observed that 
Carbopol was capable of sustaining delivery of the drug for longer period 
 
Christian fernandeset al. (2006)26formulated the Lamivudine tablets using 
HPMC and EC polymers, and developed the dissolution test conditions and evaluated the 
results by using factorial design. 
 
 Viral F. Patelet al  (2006)27 developed intragastric drug delivery system for 
Cefuroxime Axetil and employed 32 factorial design to evaluate contribution of HPMC 
K4M /K100 LV and SLS on drug release from HPMC matrix. They observed that as 
viscosity of polymers increases the release rate constant was decreased 
 
 ZiyaurRahmanet al (2006)28 developed a bilayer-floating tablet (BFT) for 
captopril using direct compression technology. HPMC, K-grade and effervescent mixture 
of citric acid and sodium bicarbonate formed the floating layer. The release layer 
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contained Captopril and various polymers such as HPMC-K15M, PVP-K30 and Carbopol 
934p, alone or in combination with the drug. The floating behavior and in- vitro 
dissolution studies were carried out in a USP 23 apparatus 2 in simulated gastric fluid 
(without enzyme, pH 1.2). °C/75% RH for three months.  
Samuel Bet al, (2006)29 inpreparation and evaluation of gastro retentive delivery 
system of flurbiprofen. In this literature they prepared hallow microspheres by using 
emulsion- solvent diffusion method, which involved co-dissolution of drug and Eudragit 
RS 100 in various ratios in ethanol: dichlormethane mix. Which was finally dispersed in 
aqueous medium .the in-vitro testing revealed that the micro sponges floated continuously 
more than 12 hours. 
C. Narendraet al(2006)30 designed gastric floating drug delivery system 
containing metoprolol tartrate as a model drug. A 23 factorial design was employed in the 
formulating the GFDDS. With total polymer content to drug ratio (X1), polymer to 
polymer ratio (X2) and different viscosity grades of HPMC (X3) as independent 
variables. Four dependent variable considered: - % of drug release at 8 h, T50%, diffusion 
coefficient and floating time. The result indicates that X1 and X2 significantly affected 
the floating time and release properties, but the effect of different viscosity grades of 
HPMC (K4M & K10M) was insignificant. 
Ali, J., Hasan et al (2006)31 in Formulation and development of Gastroretentive 
drug delivery system for ofloxacin, the hydrodynamically balanced capsules were 
prepared by physical mixing of various grades of HPMC and poly (ethylene oxide) (PEO) 
alone as well as in combinations. Cellulose acetate phthalate, liquid paraffin, and ethyl 
cellulose were used as release modifiers so as to maintain release of drug over a period of 
12 h. various grades of Eudragit and PEO were used in combination for formulating 
floating microspheres using solvent diffusion technique for preparation of multiple unit 
system.  
Sanjay S. Patelet al(2006)32 formulated floating drug delivery system containing 
Clarithromycin for helicobacter Pylori different grades of HPMC (K4M and K15M) .the 
study shows that tablets composition and mechanical strength have great influence on the 
floating properties and drug release. Incorporation of gas generating agent together with 
polymer improved drug release. The drug release was sufficiently sustained and 
anomalous diffusion as well as zero order was confirmed. 
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Girishet al (2007)33 developed bilayer and floating- bioadhesive tablets of 
Rosiglitazone maleate by using HPMC-K100M. They observed that concentration of 
HPMC K 100 M in release layer was the key factor governing drug release and in the 
bilayer drug release included the gelling agent forming a gelatinous barrier which controls 
the drug release without interference from gas bubbles generated in the floating layer. 
V.F Patelet al (2007)34 in statistical evaluation of influence of viscosity of 
polymer and type of fillers on Dipyridamole release from floating matrix tablets.This 
investigation describes the influence of HPMC and different type’s fillers o dipyridamole 
release from floating matrix tablet using 32 factorial designs. Tablets were evaluated for 
invitro floating ability and drug release study using 0.1 N HCl. from the above study it 
was observed that as viscosity of polymers increases the release rate constant was 
decreased. 
J.A. Ravalet al (2007)35 has developed ranitidine hydrochloride floating matrix 
tablets using hydrophilic matrix polymers HPMC K4M, K15 M, K100 M, sodium alginate, 
psyllum, sesbania gum, guar gum, gum acacia with or without low density polymer. 
Tablets were physically characterized and evaluated for in- vitro characteristics for 8 h in 
0.1 N HCL at 37oC .the effect of addtion of low-density copolymers and the drug release 
pattern were also studied. They observed that the tablets eroded/ swelled upon contact 
with the release medium, and the relative importance of drug diffusion, polymer swelling 
and tablets erosion on the resulting release patterns varied significantly with the type of 
matrix forming polymer. 
Basak SCet al (2007)36 designed floatable gastroretentive tablet of metformin 
hydrochlorideformulated as a floating (buoyant) matrix tablet using a gas generating 
agent (sodium bicarbonate) and a gel forming hydrophilic polymer (hydroxypropyl 
methylcellulose). The formulation was optimized on the basis of floating ability and in- 
vitro drug release. In- vitro drug release tests of these tablets indicated controlled 
sustained release of metformin hydrochloride and 96-99% released at the end of 8 h.  
Dasarath M. Patelet al (2007)37 prepared Gastro retentive drug delivery system 
of Carbamazepine: formulation optimization using simplex lattice design .the tablets were 
prepared by using Beeswax, HPMC K4M. Ethyl cellulose as a floating enhancer. The 
prepared tablets were evaluated for in- vitro drug release in simulated gastric fluid (pH 
1.2). The release profile of promising formulation fitted best to zero-order model. The 
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factorial batches were subjected to short –term stability studies at 400 c and 75% relative 
humidity for 3 months. 
Javed Aliet al(2007)38 developed a hydrodynemically-balanced system of 
metformin as single unit floating capsule. Various grades of low-density polymer such as 
PEO and HPMC K4M were used for formulating the system. The formulation was 
optimized on the basis of in-vitro buoyancy and in- vitro release in simulated fed state 
gastric fluid. They observed that the optimized HBS formulation of metformin could 
sustain the drug release in addition to remaining buoyant in the stomach as revealed by 
Gamma scintigraphic images. 
Manoj N. Gambhireet al  (2007)39 developed floating drug delivery system of 
diltiazem HCL using HPMC K 100M and compritol 888 ATO. They investigated the effect 
of sodium bicarbonate succinic acid on the drug release profile and floating properties. A 
32 factorial design was applied to systematically optimize the drug release profile. The 
linear regression analysis and model fitting showed that all these formulation followed 
Korsmeyer and Peppas model, which had a higher value of correlation coefficient. While 
the tablets hardness had little or no effect on the release kinetics and was found to be a 
determining factor with regards to the buoyancy of the tablets. 
Shivakumar HNet al (2007)40 inOptimization of Gastroretentive System for Oral 
Controlled Delivery of Cinnarizine Using Response Surface Methodology.A controlled 
release effervescent floating system is proposed for gastroretentive delivery of 
cinnarizine. The effect of the formulation variables such as levels of HPMC K4M (X1), 
sodium bicarbonate (X2) and citric acid (X3) on the tablet floating characteristics and 
drug release was studied.  
Tejaspatelet al (2008)41 formulated gastric floating drug delivery system for 
ranitidine HCL. HPMC of different viscosity grades and carbopol 934 P was used in 
formulating the GFDDS. Employing 23 full factorial designs. They observed that the 
HPMC, the presence of carbopol and their interaction had significant impact on the drug 
release and floating properties of the delivery system. The decrease in the release rate was 
observed with increase in the viscosity of the polymeric system. 
Pravinchaudhriet al(2008)42 developed bilayered floating tablets for Tizanidine 
HCL using HPMC- Gelucire 43/01, and HPMC- xanthan gum. They observed that the use 
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of high viscosity polymer can also decreased the floating lag time but this use of high 
viscosity polymer increase the matrix integrity and resultant weight. 
Swamy P.V et al (2008)43 designed gastro retentive drug delivery of Atenolol by 
using HPMC of different viscosity grades (K4M and 50 cps) and sodium bicarbonate as a 
gas-generating agent to reduce the floating lag time. Six batches of preliminary trials 
formulations were designed and from the results of evaluation, the constraints for 
independent variables X1 (amount of HPMC 50 cps) and X2 (amount of sodium 
bicarbonate) have been fixed.  
  
Ravikumaret al  (2009)44formulated and evalvuated effervescent floating tablet 
of famotidine by developing a floating delivery system using gas forming agents 
like,sodiumbicarbonate,citricacid,and hydrocolloids like HPMCandCarbopol 934P 
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3. AIM AND OBJECTIVES 
 
Aim:Formulation and Evaluation of Cefixime Floating Matrix tablet Using (Controlled 
drug Release tablet) to treat Bacterial infections to improve the patient compliance. 
 
Objectives: 
 
• To improve the time bounded system of cefixime Matrix tablet. 
 
• Develop a floating Matrix tablet of cefixime by direct compression 
method. 
 
• To conduct Preformulation study of the drug with excipients. 
 
• To study the effect of polymer concentration on drug release. 
 
• To study the effect of fillers on drug release. 
 
• To check for drug excipient compatibility. 
 
• To conduct the different formulations. 
 
• To evaluate the formulated floating Matrix tablet. 
 
• To conduct the In-vitro drug release of the formulated floating Matrix 
tablet. 
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4.PLAN OF WORK 
The main objective of the study i.e. Formulation and Evaluations of floating matrix 
tablet of cefixime (Controlled drug release tablet) can be achieved by following plan of work. 
      
Literature Review 
 
 
Preformulation studies 
 
Formulation  
 
Evaluation of the matrix tablet 
 
Results & Discussion 
 
FIG-2: Process flow chart 
 
Drug(cefixime) & Excipient profile 
                                                                          Drug Profile 
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DRUG PROFILE 
 
CEFIXIME 
 
Synonym: Cefixim, Cefixima, Cefiximum 
 
Chemical names: (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxy) 
imino]acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. 
 
Molecular Weight: 453.45 
Molecular formula: C16 H15 N5 07S2 
Structure of compound: 
 
 
 
 
 
Description: It is an orally active third generation cephalosporin highly active against 
Enterobactriaceae, H. influenzae and is resistant to may β-lactamases.  However, it is not 
active on Staph, aureus, most pneumococci and Pseudomonas.  It is a white to almost 
white, powder, odourless to practically odourless powder.  With melting point at 2070C. 
 
Solubility: Practically insoluble in water soluble in HCL. 
 
Storage: Store at 200 – 2500C (680 – 770F).  Dispense in well-closed containers with 
safety closures. 
Category: β-lactum antibiotic . 
 
 
                                                                          Drug Profile 
 
Department of pharmaceutics, Cherraan’s College of Pharmacy, Coimbatore.      38 
 
 
Pharmacokinetics and Pharmacodynamics:   
Absorption: Bioavailability40%- 50%, absorb from the GI tract. T max is about 2 to 3 h. 
Food: T max increased and C max and AUC are slightly decreased. 
 
Distribution: Vd is 8.8 L.  Protein binding is more than 99.5%. 
Metabolism: Completely metabolized by oxidation via CYP-450 2C9.  Major metabolites 
are cyclohexylhydroxymethyl (M1) (about one-third of the activity of the parent) and 
carboxyl (M2) derivatives. 
 
Elimination: About 60% is excreted in urine and about 40% in faces as metabolites. 
The half-life is about 3 to 4.2h. 
 
Cefixime: is used with diet to reduce bacterial infections. 
Pharmacology: Cefixime, an antibiotic, is a third-generation cephalosporin like 
ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase 
enzymes. As a result, many organisms resistant to penicillins and some cephalosporins 
due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial 
effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell 
wall. 
Uses: β-lactum antibiotic to treat bacterial infections. 
Ear: Otitis caused by Haemophilus influenzae, Moraxella atarrhalis and Streptococcus 
pyongenes. 
Sinuses: Sinusitis. 
Throat: Tonsillitis, pharyngitis caused by Streptococcus pyogenes. 
Chest and lungs: Bronchitis, pneumonia caused by Streptococcus 
pneumoniae and Haemophilus influenzae. 
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Dose: Adults – 200 – 400 mg daily (max 200 mg /day initial dose) with breakfast or the 
first main meal of the day.  Increase by 200 to 400 mg /dose. 
 
Adverse effects: Adverse drug reactions include diarrhea, dyspepsia, nausea and 
vomiting. Hypersensitivity reactions like skin rashes, urticaria and Stevens-Johnson 
syndrome have been reported. There is no specific antidote for Cefixime overdosage. 
Gastric lavage may perform. Dialysis will not remove Cefixime in significant quantities. 
Contraindication: Cefixime is contraindicated in patients with known sensitivity or 
allergies to cephalosporin class of antibiotics. As Cefixime is a third generation 
cephalosporin, it is not contraindicated for patients with a true penicillin allergy.  
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Lactose: 
Nonproprietary Names: 
BP: Anhydrous Lactose, JP: Anhydrous Lactose, PhEur: Lactose, Anhydrous, USP-NF: 
Anhydrous Lactose.  
Synonyms: 
 Anhydrous Impalpable; Anhydrous 60M; lactosumanhydricum; saccharumlactis; 
milk sugar 
Chemical Name:  
O-b-D-Galactopyranosyl-(14)-b-D-glucopyranose 
Empirical Formula: C12H22O11 
Molecular Weight: 342.30  
Physical Properties: 
 White to off-white powder or crystal particles. Lactose Contains 70-80% of β- 
Anhydrous Lactose and 20-30% of α- Anhydrous Lactose. 
Solubility: Soluble in water and insoluble in chloroform, ethanol, and ether. 
Melting Point: 232.00C 
Applications and Uses: 
 Anhydrous lactose is widely used in direct compression tableting applications, and 
as a tablet and capsule filler and binder. Anhydrous lactose can be used with moisture-
sensitive drugs due to its low moisture content. It may also be used in intravenous 
Injections. Used as lyophilization aid and Dry powder inhaler carrier.  
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HYDROXY PROPYL METHYL CELLULOSE
Nonproprietary Names 
BP:   Hypromellose 
USP:  Hydroxy propyl methyl cellulose
Synonyms 
Benecel MHPC, Cellulose, Hydroxy propyl methyl 
ether,E464,HPMC,Methocel,Methyl cellulose, Propylene glycol ether, methyl hydroxyl 
propyl cellulose, Metolose, Pharmacoat
Chemical name 
Cellulose, 2-hydroxy propyl methyl ether
Empirical formula 
                      [CH3CH(OH)CH2]
Molecular weight 
10,000-1, 50,000 
Structural formula 
Functional Category 
Coating agent, film-former, rate controlling polymer for sustained permeation, 
stabilizing agent, suspending agent, tablet binder, viscosity increasing agent.
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Application in pharmaceutical formulation technology 
HPMC is widely used in oral and topical pharmaceutical formulation. In topical products,     
HPMC is also used as a suspending and thickening agent. 
Description 
It is an odorless and tasteless, white or creamy-white colored fibrous or granular 
powder. 
Typical properties 
Bulk density: 0.341g/cc 
Tap density: 0.557g/cc 
True density:1.326g/cc 
Viscosity: HPMC K4M, 4000 CPS; K10M 10,000 CPS 
Methoxy content: 19-24% 
Hydroxyl propoxy content: 7-12% 
Melting point 
Browns at 190-200 ºc, chars at 225-230ºc, glass transition temperature is 170-
180ºc 
Moisture content 
Hydroxyl propyl methyl cellulose absorbs moisture from the atmosphere, the 
amount of water absorbed depending open the initial moisture content and temperature 
and relative humidity of the surrounding air. 
Solubility 
 Soluble in cold water, mixtures of ethanol dichloromethane, mixtures of methanol 
and dichloromethane. 
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Specific gravity: 1.26 
Stability and storage condition 
Hydroxyl propyl methyl cellulose powder is stable material although it is 
hygroscopic after drying. Solutions are stable between PH 3-11.Increasing temperature 
reduce viscosity of solutions. Aqueous solutions are comparatively enzyme resistant, 
providing good viscosity stability. 
Hydroxyl propyl methyl cellulose powder should be stored in a well closed 
container in a cool and dry place. 
Incompatibilities 
Hydroxyl propyl methyl cellulose is incompatible with some oxidizing agents. 
Since it is nonionic, hydroxyl propyl methyl cellulose will not complex with metallic    
salts or ionic organics to form insoluble precipitation.    
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CARBOPOL  
  Carbopols (carbomers) are synthetic high-molecular-weight polymers of acrylic acid that 
are cross-linked with either allyl sucrose or allyl ethers of pentaerythritol. They contain between 
56% and 68% of carboxylic acid (COOH) groups calculated on the dry basis. 
Types: Carbomer 910, 934, 934P, 940, 941, 971P, 974P and 1342  
Nonproprietary Names 
• BP    : Carbomers 
• PhEur    : Carbomers 
• USP-NF : Carbomer 
Synonyms 
Acrypol; Acritamer; acrylic acid polymer; carbomera; Carbopol; carboxypolymethylene; 
polyacrylic acid; carboxyvinyl polymer; Pemulen; TegoCarbomer. 
Structure:  
 
Figure : Chemical structure of carboxypolymethylene 
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Description: 
 
  White-Colored,‘fluffy’, Acidic, hygroscopic powders with slight characteristic   odour. 
Solubility:  
  Soluble in water after neutralization, in ethanolic (95%) and glycerin. 
Density: 
  1.76-2.08 g/cm3 (bulk); 1.4 g/cm3 (tapped) 
Stability: 
  Dry powder forms do not support the growth of molds and fungi. Microorganisms grow 
well in unpreserved aqueous dispersions and therefore an antimicrobial preservative such as 
chlorocresol (0.1%), methyl paraben (0.18%) & propyl paraben (0.02%), or thiomersol (0.1%) 
should be added. Exposure to light causes oxidation that is reflected in a decrease in dispersion 
viscosity. Stability to light may be improved by the addition of 0.0-0.1% w/v of a water soluble 
UV absorber such as benzophenone-2 or benzophenone-4 in combination with 0.05-0.1% w/v 
edetic acid. The UV stability of carbomer gels may also be improved by using triethanolamine as 
the neutralizing base. 
Uses: 
 Suspending or viscosifier in liquid or semisolid dosage forms,  Emulsifying agent for 
emulsions meant for external use. 
 Dry or wet binder, rate controlling polymer and Sustained-release matrix beads. 
 Bioadhesive for a cervical patch and magnetic granules for site  specific drug delivery to 
the Oesophagus and in oral mucoadhesive controlled drug delivery system. 
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EUDRAGIT RS 100 
 
 
Eudragit RS100 is copolymers of methacrylic acid esters containing an amount of 
quaternary ammonium groups between 4.5-6.8%. Eudragit RS 100 is insoluble in water 
and digestive juices,pbut permeable has pH-independent release profiles. 
Class                 :               Ammonio Methacrylate copolymer Type B”Ph. Eur.  
Molecular wt    :                150,000. 
Description       :               Colourless, clear to cloudy granules with a faint amine- 
         like odur 
Solubility          :               miscible with methanol, ethanol and isopropyl alcohol  
        (containing 
Approx.3% water), as well as acetone, chloroform, ethyl acetate       
And methylene chloride in a ratio of 1:1. 
Viscosity          :               Max. 15 mPa.s 
Stability           :                Stable under ordinary conditions of storage 
Storage            :                Protect from warm temperatures and against moisture. 
                                         Keep in tightly closed containers. 
 
 
                                                                                             Excipients profile 
 
Department of pharmaceutics, Cherraan’s College of Pharmacy, Coimbatore. 47 
 
 
Uses                :                time controlled release of active ingredients  
                                         Therapeutically customized release profiles 
                                          Higher patient compliance due to reduced  
                                          Number of doses to be taken 
Application    :                                                                         
 Simple taste masking through gastric resistance to controlled drug release in all 
selections of the intestine insoluble but permeable in digestive fluids.  
 Eudragit RS polymer with alkaline enable controlled release of  active ingredient 
by pH-independent swelling. 
 Delayed and sustain drug release    
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SODIUM BICARBONATE53 
Non-proprietary Names : BP/EP: Sodium bicarbonate  
Synonym   :  Baking soda, E-500, Monosodium carbonate.  
Chemical name : Carbonic acid, Monosodium salt, Monosodium          
carbonate.  
Empirical formula  : NaHCO3  
Molecular weight  :  84.01 
Category   : Alkalizing Agent, Therapeutic Agent.  
Description :   It is an odorless, white crystalline powder with 
 slight alkaline taste.  
Acidity/ Alkalinity   :   pH 8.3 for freshly prepared 0.1M aqueous solutions 
 at 250C. 
Density              :  2.159 g/cm3 
Solubility   :  Soluble in water, practically insoluble in ethanol.  
 
Stability and Storage: 
Sodium bicarbonate is stable in dry air but slowly decomposes in                                   
moist air and should therefore be stored in well-closed container in a cool dry place. 
Orally ingested sodium bicarbonate neutralizes gastric acid with the evolution of 
carbon dioxide and may cause stomach cramps and flatulence. 
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CITRIC ACID ANHYDROUS
Nonproprietary Names 
BP: Citric acid monohydrate, 
USP: Citric acid 
Synonyms: E330; 2-hy droxypropane
Chemical Name: 2-Hydroxy
Empirical Formula and Molecular Weight
Structure: 
Functional Category: Acidifying agent
flavor enhancer. 
Applications in Pharmaceutical Formulation or Technology
 Citric acid (as either the monohydrate or anhydrous material) is widely used in 
pharmaceutical formulations and food products,
 Primarily to adjust the pH of solutions. It has also been used experimentally to 
adjust the pH of tablet matrices in enteric coated formulations for colon
delivery 
Solubility: soluble 1 in 1.5 parts of ethanol (95%) and 1 in less than 1 part of w
sparingly soluble in ether. 
Stability and Storage Conditions:
 Citric acid loses water of crystallization in dry air or when heated to about 408C. 
It is slightly deliquescent in moist air. Dilute aqueous solutions of citric acid may ferment 
on standing. The bulk monohydrate or anhydrous material should be stored in airtight 
containers in a cool, dry place.
Excipients profile
 
IP: Citric acid, PhEur: Acidumcitricummonohydricum
-1, 2,3-tricarboxyl ic acid monohydrate. 
-1, 2, 3-propanetricarboxylic acid monohydrate 
: C6H8O7_H20 210.14  
 
; antioxidant; buffering agent; chelating agent; 
 
 
-
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TALCUM POWDER(TALC) 
Non-proprietary Names: 
 BP    -  Purified Talc 
 JP    -  Talc 
 PhEur    -  Talc 
 USP    -  Talc 
Synonyms: 
 Altalc; E553b; hydrous magnesium calcium silicate; hydrousmagnesium silicate; 
Imperial; Luzenac Pharma; magnesium hydrogenmetasilicate; MagsilOsmanthus; Magsil 
Star; powdered talc;purified French chalk; Purtalc; soapstone; steatite; Superiore;talcum. 
Chemical Name and CAS Registry Number: 
   Talc -14807-96-6. 
Empirical Formula and Molecular Weight: 
 Talc is a purified, hydrated, magnesium silicate, approximating tothe formula 
Mg6(Si2O5)4(OH)4. It may contain small, variableamounts of aluminium silicate and iron. 
Physical appearance :fine ,light and white colour powder. 
Identification: 
• Microscopy: Irregular plats , the majority less than 50µm in length. 
• Melt 0.5gm in a metal crucible with 1gm of potassium nitrate and 3gm of 
anhydrous sodium carbonate, add 20ml of boiling water ,mix and filter . 
wash the residue with 50ml of water . mix residue with a mixture of 0.5ml 
of HCL acid and 5ml of water and filter. to the filtrate a 1ml of 9M 
ammonia and 1ml of ammonium chloride solution and filter .To the filtrate 
add 1ml of di-sodium hydrogen phosphate solution a white , crystalline 
precipitate is produced.    
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Description:  
  Talc is a very fine, white to greyish-white, odourless, impalpable,unctuous, 
crystalline powder. It adheres readily to the skin and issoft to the touch and free 
from grittiness. 
Applications in Pharmaceutical Formulation: 
• Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluents, although today it is less commonly used. However, it is widely used 
as a dissolution retardant in the development of controlled-release products. 
• Talc is also used as a lubricant in tablet formulations. 
• In a novel powder coating for extended-release pellets, and as an adsorbent. 
• In topical preparations talc is used as a dusting powder, although it should not 
be used to dust surgical gloves. 
• Talc is a natural material; it may therefore frequently contain microorganisms 
and should be sterilized when used as a dusting powder. 
• Talc is additionally used to clarify liquids and is also used in cosmetics and 
food products, mainly for its lubricant properties. 
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MAGNESIUM STEARATE 
Non-proprietary name:  
BP, JP, PhEur, and USP: Magnesium stearate. 
Synonym:  
 Dibasic magnesium stearate, magnesium distearate, magnesium octadecanoate, 
stearic acid. 
Chemical name: Octadecanoic acid magnesium salt. 
Empirical Formula and Molecular weight:C36H70MgO4 - 591.24. 
Structural Formula:[CH3 (CH2)16COO]2M. 
FunctionalCategory:Tablet and capsule lubricant. 
Physical appearance:Fine, light, white precipitated or milled, impalpable powder. 
Description: 
 Magnesium stearate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odour of stearic acid and a characteristic taste. 
The powder is greasy to the touch and readily adheres to the skin. 
Solubility: 
 Practically insoluble in water, ethanol, and ether. Soluble in warm benzene, and 
warm ethanol. 
Melting point: 117-1500C. 
Identification: 
 5mg of powder add 50ml of ether 20ml of 2M nitric acid and 20ml of distilled 
water and heat under a reflex condenser until dissolution is completed. Allow to cool, 
separate the aqueous layer and shake the ether layer with two quantities, Each 4ml of 
distilled water , combine the aqueous layer , wash with 15ml of ether & dilute to 50ml 
with distilled water. Evaporate the ether layer to dryness and dry the residue at 105oC the 
freezing point of the residue is not lower than 53oC .To 1ml of solution A obtained in test 
A given reaction A of magnesium salt.  
Applications: 
• Magnesium stearate is widely used in cosmetics, foods, and 
pharmaceutical formulations.  
• It is primarily used as at lubricant in capsule and tablet manufacture at  
  concentrations between 0.25% and 5.0% w/w.  
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  MATERIALS AND METHODOLOGY 
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 Pre compression parameters 
 Post compression parameters 
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MATERIALS 
Table:3 List of materials 
Materials  Supplier 
Cefixime (API)  Lara Labs Ltd, Hyderabad, A. P., India 
Lactose(Diluent)  Lara Labs Ltd, Hyderabad, A. P., India 
   
HPMC K100 (Rate control in polymer)   Lara Labs Ltd, Hyderabad, A. P., India 
   
Carbopol (Rate control in polymer)  Lara Labs Ltd, Hyderabad, A. P., India 
   
Eudragit (Rate control in polymer)  Lara Labs Ltd, Hyderabad, A. P., India 
   
Sodium bicarbonate  
(Gas Generating Agent) 
 
Lara Labs Ltd, Hyderabad, A. P., India 
   
Citric acid (Gas Generating Agent)  Lara Labs Ltd, Hyderabad, A. P., India 
Magnesium stearate (Lubricant)  Lara Labs Ltd, Hyderabad, A. P., India 
   
Talc (Lubricant)  Lara Labs Ltd, Hyderabad, A. P., India 
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EQUIPMENTS/INSTRUMENTS 
Table 4  List of equipments/ instruments 
 
Equipment’s  Model/Company 
Electronic balance  Shimadzu AUX220, Japan. 
Tablet compression machine  Lab India Ltd., India 
Tablet hardness tester  Pfizer hardness tester 
Dissolution test apparatus  Electrolab, India 
Friability test apparatus  Roche Friabilator(USP), Electrolab, India 
UV-Visible Spectrophotometer       Shimadzu UV-1800, Japan 
FTIR spectrophotometer       Bruker (Tensor 27) 
Tap density taster        Electrolab, India 
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METHODS: 
Preformulation study: 
Estimation ofCefixime: 
Preparation of standard solution: 
 Equivalent 500mg of the pure Cefixime trihydratewas weighed and transferred 
into 50ml volumetric flask. The drug was then dissolved and diluted up to the mark with 
0.1N Hcl to get a concentration of 1000µg/ml of stock solution 1. 2ml of stock 1 solution 
was taken and diluted to 100 ml to give 20µg/ml solution. 
Preparation of working standard solutions 
 From the stock solution 2 aliquots were pipetted out 2.5, 3.75, 5, 6.25, and 7.50ml 
and transferred to 25 ml volumetric flasks and diluted up to the mark with acidic buffer 
pH 1.2 to get concentration of 50, 75,100,125, and 150µg/ml, respectively. The 
absorbance of the solutions was measured at λmax235.0 nm using double beam UV-visible 
spectrophotometer (UV1800, Shimadzu, Kyoto, Japan) against suitable mixture as a 
blank. The plot of absorbance vs. concentration (µg/ml) is plotted & data was subjected to 
linear regression analysis in Microsoft excel (2007).The obtained results are given in 
Table 5.1 and Figure 5.2. 
0.1NHcl  Preparation 
 8.5ml of concentrated Hcl measured and transfer in 1ltr beaker dil. with water mix 
properly then make up to 1000ml.   
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Drug-excipients interaction study: 
Fourier Transform infra-red (FTIR) spectroscopy: 
 Infrared spectroscopy is a useful analytical technique utilized to check the 
chemical interaction between the drug and excipients used in the formulation.1-2 mg of 
solid fine powder of cefixime and 200-300 mg of dry powder of KBr(IR grade) were 
taken in a mortar and mixed well with the help of a spatula. Spectrum measurement was 
carried out using KBr disk method in the wavelength region of 2000-400cm-1 by FTIR 
spectrophotometer. The IR spectrum of the physical mixture was compared with that of 
the pure drug to check any possible drug-excipient interaction. 
Table.5 
              Composition of Cefixime GRDDS by Direct Compression Method  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Composition(mg/tab) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Cefixime 200 200 200 200 200 200 200 200 200 
Lactose 90 40 90 40 90 40 140 140 140 
Hpmc K100 100 150 - - - 50 - - - 
Carbopol - - 100 150 - - - 50 - 
Eudragit - - - - 100 150 - - 50 
Sodium bicarbonate 80 80 80 80 80 80 80 80 80 
Citric acid 20 20 20 20 20 20 20 20 20 
Talc 5 5 5 5 5 5 5 5 5 
Magnesium 
stearate 
5 5 5 5 5 5 5 5 5 
Total 500 500 500 500 500 500 500 500 500 
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Formulation of floating tablets of cefixime by direct compression method: 
Procedure: Floating tablets of Cefixime were prepared by direct compression method 
employing sodium bicarbonate as gas-generating agent. HPMC K100, Carbopol, and 
Eudragit were used as rate controlling polymers. The concentrations of the above 
ingredients were optimized on the basis of trial preparation of the tablets. All the 
ingredients [Table ] were weighed accurately. The drug was mixed with the release rate 
retarding polymers and other excipients, except talc and Magnesium stearte, in ascending 
order of their weight. The powder mix was blended for 20 minutes to have 
uniformdistribution of drug in the formulation. Then, Magnesium stearate was added and 
mixed for not more than 1 minute (to ensure good lubrication.)About 500 mg of the 
powder mix was weighed accurately and fed into the die of single punch machinery and 
compressed using 12mm flat- surface punches.The hardness of the tablets was adjusted at 
4-5 kg/cm2 using a Pfizer hardness tester.  
 
Pre compression parameters: 
Angle of Repose: - The angle of repose is the constant, three dimensional angle (relative 
to horizontal base) assumed by a cone like pile of material formed by any of several 
different methods. When the angle of repose exceeds 50 degrees, the flow is rarely 
acceptable for manufacturing purposes. 
Table  6  Angle of Repose with flow properties 
Flow properties Angle of Repose (degrees) 
Excellent up to 20 
Good 20 to 30 
Fair / Reasonable 30 to 40 
Flow with difficulty above 40 
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Bulk density, Tapped density, % Compressibility index & Hausner ratio: 
a. Apparent Bulk Density:The bulk density was determined by transferring the 
accurately weighed sampleof powder to the graduated cylinder. The initial volume and 
weight was noted. Ratio of weight of the sample was calculatedby using the following 
formula. 
Density = Mass/Volume. 
b. Tapped Density: Weighed powder sample was transferred to a graduated cylinder and 
was placedon the tap density apparatus, was operated for fixed number of taps (500). The 
tapped density was determined by the following formula. 
Density = Mass/Tapped Volume. 
c. Percentage Compressibility:  Based on the apparent bulk density and the tapped 
density, the percentage compressibility of the bulk drug was determined by the following 
formula. 
% Compressibility = Tapped density – Bulk density *100/ Tapped density 
                      Table: 7 % Compressibility limits with respect to flowability   
S.No %Compressibility Flow ability 
1 5-12 Excellent 
2 12-16 Good 
3 18-21 Fair 
4 23-25 Poor 
5 33-38 Very poor 
6 More than Very very poor 
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d. Hausner’s Ratio:  It indicates the flow properties of powder and is measured by the 
ratio of tap density to bulk density. 
                      Hausner ratio   =    Tapped density/Bulk density 
  Table:8  Hausner ratio limits as per IP 
Hausner’s ratio Type of flow 
< 1.25 Good flow 
> 1.25 Poor flow 
 
e. Drug to Polymer compatibility Study: 
The IR spectrums of Cefixime & dosage forms containing polymers (HPMC, Eudragit 
carbopol ) were recorded using ???Alpha Brooker FTIR (Tokyo, Japan).using pellate 
technique. All these results are shown in figure  
Post compression parameters: 
Hardness 
 The hardness of ten tablets was found using Pfizer Hardness tester. Mean and 
standard deviation were computed and reported. It is expressed in kg/cm2. 
Friability 
 The friability of the tablets was determined using Roche friabilator(Remi 
Electronics, Mumbai, India). It is expressed in percentage.10 tablets were initially 
weighed and transferred into the friabilator. The friabilator was operated at 25 rpm for 
four minutes. After four minutes the tablets were weighed again. The % friability was 
then calculated using the formula:  
WeightInitial
xWeightFinalWeightInitialFriabilityof 100% −=
 
  Acceptable weight loss: NMT 0.5-1% 
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Weight variation 
 Twenty tablets were individually weighed and average weight was calculated. The 
individual weight was compared to the average weight. The tablets pass the test if not 
more than two tablets are outside the percentage limit and if no tablet differs by more than 
two times the percentage the percentage limit. The weight variation tolerance for 
uncoated tablets is as follows: 
 
Table: 9 Standard weight variation limits (USP) 
Average Tablet weight % Deviation 
130mg 10 
>130mg-324mg 7.5 
>324mg 5 
 
% Deviation =Average weight – Tablet weight *100/. Average weight          
 
1. Thickness: The thickness of the tablets was determined using. Vernier Calipers.  
Five tablets from each batch were used. The results are shown in Table ???. 
2. Content Uniformity Test: 
 For determination of drug content three tablets from each formulation were 
weighed individually, crushed and a quantity of powder equivalent to 100mg weighed 
and is dissolved in 100ml of water to give a solution of 1mg/ml. 1.0 ml of this 
solution was further diluted up to 10.0 ml with distilled waterto give a solution of 
concentrations 100 ugm/ml. Then aliquot of the filtrate was diluted suitably and 
analyzed spectrophotometrically at 258 nm against blank. 
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Amount of drug release =   Conc×dilution factor× wt of tablet 
i. 1000× wt of sample 
 
 
%Drug release =     Amount of drug release×100 
ii. Label claim 
 
  Table:10  Content uniformity limits 
Number of tablets Acceptable criteria 
9 out of 10 85-115% 
1 may be 75-125% 
27 ut of 30 85-115% 
2 may be 75-125% 
 
Dissolution studies:  
 The in-vitrorelease of Cefiximefrom formulated tablets was carried out for 24 
hours in 0.1N Hcl. The studies were performed in USP dissolution apparatus II 
(Electrolab, Mumbai, India) at 37 ± 0.5° C and 50 rpmspeed. Samples were taken at 2, 4, 
8, 16, 20 & 24hours and diluted to suitable concentration and analyzed for Cefixime 
content at 235 nm by using UV–visible spectrophotometer The values are shown in Table 
24 and plots for the same are shown in Figure 22&23.  
% Drug release= Amount of drug released ×100
 
  Label claim       
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TABLE Standard dissolution parameters 
 
 
Swelling Index36 : 
 This was measured in terms of percentage(%) weight gain by the tablet. First 
prepare the  0.1NHcl take for each formulation separate Petri-dish and pour the buffer 
into the Petri-dish, insert the tablet in according the sequence and measure the % gain of 
the tablet with the interval . 
S.No Parameters Specification for 
formulation’s 
1 Petri-dish Glass material 
2 Medium 0.1 Hcl 
3 Time interval 2hours (up to 24 hours) 
 
Table:16  list of parameter for Swelling Index 
   
  The % weight gain of the tablet was calculated by the following formula, 
    S.I={(Mt - Mo) / Mo}  x 100 
Where, 
  S.I = swelling index 
  Mt = weight of the tablet at the time(t) and 
  Mo=weight of the tablet at the time(t) = 0 
 
 
 
Stage No.of tablets Acceptance criteria 
S1 6 No tablet<D+5% 
S2 6 Avg of 12tab > D; No unit<D_15% 
S3 
 
12 
Avg of 24 tab, S1+S2+S3>D 
NMT 2 tab<D_15%, No unit<D_25% 
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Drug release kinetics: 
 Dissolution data of above two methods was fitted in Zero order, First order 
and Higuchi equations. The mechanism of drug release was determined by using Higuchi 
equation. 
• Zero-Order Kinetics: 
Zero order as cumulative amount of drug released vs time, 
C = K 0 t 
 Where K0 is the zero-order rate constant expressed in units of concentration/time 
and t is the time in hours. A graph of concentration Vs time would yield a straight line 
with a slope equal to K0 and intercept the origin of the axes.  
• First order kinetics: 
First order as log cumulative percentage of drug remaining vs time,  
L o g C = L o g Co − k t / 2.303 
Where C0 is the initial concentration of drug, k is the first order constant, and t is the time. 
A graph of log cumulative of % drug remaining vs time yields a straight line. 
• Higuchi Model: 
Higuchi’s model as cumulative percentage of drug released vs square root of time  
Q = K t 1 / 2 
Where K is the constant reflecting the design variables of the system and t is the time in 
hours. Hence, drug release rate is proportional to the reciprocal of the square root of time. 
A graph of cumulative % drug released vs square root t yields a straight line 
• Korsemayer Peppas equations: 
To evaluate the mechanism of drug release from Disulfiram implant, data for the first 
60% of drug release were plotted in Korsmeyer et al’s equation log cumulative 
percentage of drug released vs log time, and the exponent n was calculated through the 
slope of the straight line.  
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M t / M ∞ = K t n 
Where, Mt/M∞ is the fractional solute release, t is the release time, K is a kinetic constant 
characteristic of the drug/polymer system, and n is an exponent that characterizes the 
mechanism of release of tracers. For cylindrical matrix tablets, if the exponent n = 0.45, 
then the drug release mechanism is Fickian diffusion, and if 0.45 <n< 0.89, then it is non-
Fickian or anomalous diffusion. An exponent value of 0.89 is indicative of Case-II 
Transport or typical zero-order release.  
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PREFORMULATION STUDY10: 
 Preformulation studies are the first step in development of dosage form of a drug 
substance. Preformulation studies are performed to develop a portfolio of information 
about the drug substance, so that this information is useful to develop formulation. 
 "Preformulation" can be defined as investigation of physical and chemical 
properties of drug substance alone and when combined with excipients. 
Goals of Preformulation: 
1) To establish the necessary physicochemical parameters of  a new drug 
substance 
2) To determine its kinetic rate profile 
3) To establish compatibility with common excipients 
Physicochemical parameters: 
• Solubility of drug 
• Particle size 
• Bulk density 
• Tapped density 
• Carr’s index & Hausner ratio 
• Flow property (Angle of Repose) 
• F.T.I.R spectra 
Organoleptic Properties: 
 Physical characterization of drug components was observed, such as color, odor, 
and appearances of the Active Pharmaceutical Ingredients(API) were examined. 
Melting Point: 
 The point at which the drug or Active Pharmaceutical Ingredient was melts into 
liquid. This phenomenon helps in the characterization of the API polymorphism, presence 
of impurities, degradation and drug excipient compatibility. 
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Solubility: 
 It is the phenomenon that relates the drug in solid state, forms solution on contact 
with solvent. According to the BCS classification based on solubility the components are 
said to be given follow. 
• very soluble (Class І and Class ІІІ) and 
• poorly soluble (Class ІІ and class ІV). 
 The solubility of the API’s (Active Pharmaceutical Ingredient)checked in 4 types 
of solvents such as water, 0.1N HCl, pH 4.5 Acetate buffer, pH 6.8 Phosphate buffer, and 
pH 7.2 Phosphate buffer 
Density: 
  The ratio between weight to volume called as density. It is expressed as gm/cc. 
Determination of bulk density: 
 Weigh accurately 25 g of blend (W), which was previously passed through 20 # 
sieve and transfer in 100 ml graduated measuring cylinder. Carefully level the powder 
without compacting, and read the unsettled apparent volume (V0). Calculate the apparent 
bulk density in gm/ml by the following formula; 
  Bulk density = Weight of powder / Bulk volume 
Determination of tapped density: 
 Weigh accurately 25 g of blend, which was previously passed through 20 # sieve 
and transfer in 100 ml graduated measuring cylinder. Then mechanically tap the cylinder 
containing the sample by raising the cylinder and allowing it to drop under its own weight 
using mechanically tapped density tester that provides a fixed drop of    14± 2 mm at a 
nominal rate of 300 drops per minute. Tap the cylinder for 500 times initially and 
measure the tapped volume (V1) to the nearest graduated units, repeat the tapping an 
additional 750 times and measure the tapped volume (V2) to the nearest graduated units. 
If the difference between the two volume was less than 2 % then final the volume (V2). 
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 Tapped density = W/Vt gm/ml 
 W = weight of the blend 
         Vt = Tapped volume 
Carr's compressibility index &Hausner's Ratio: 
 The compressibility index and Hausner ratio were measure the propensity of 
powder to be compressed. Carr’s compressibility index and Hausner's ratio can be 
calculated as follows; 
 
′	 =
 − 

∗  
 
 =


 
 
Compressibility 
index (%) 
Flow 
character 
Hausner 's 
Ratio 
< 10 Excellent 1.00–1.11 
11–15 Good 1.12–1.18 
16–20 Fair 1.19–1.25 
21–25 Passable 1.26–1.34 
26–31 Poor 1.35–1.45 
32–37 Very poor 1.46–1.59 
>38 Very, very 
poor 
>1.60 
Table:  Flow character related to Compressibility index and Hausner ratio 
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Angle of repose: 
 The maximum possible angle between the height of the pile to the surface of the 
plane. The frictional force in the powder can be measured by the angle of repose. Angle 
of repose was calculated by fixed funnel method. The funnel was fixed to a measured 
height. The powder blend was allowed to flow through funnel onto the surface until the 
apex of the heap touches the tip of the funnel. And the diameter of the heap was 
measured. Angle of repose was calculated by following formula; 
 
 tan  =


 
Where, 
 h  =  Height of the powder heap in cm. 
r  =  Radius of heap in cm. 
 
Angle of 
repose (Ө) 
Predicted flow property 
25-30 Excellent 
31-35 Good 
36-40 Fair (Aid not needed) 
41-45 Passable (May hang up) 
46-55 Poor (Must agitate or vibrate) 
56-65 Very poor 
>66 Very very poor 
 
Table:  Angle of Repose related Flow Property 
 
  Angle of repose were calculate by given above methods and the flow 
property will decided according the above table. 
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F.T.I.R SPECTRA: 
 IR spectra of bulk drugs were taken using F.T.I.R Spectrophotometer             
(F.T.I.R: Shimadzu 1200 S, JAPAN). F.T.I.R spectrum of drug was taken by using KBr 
pellet method. Pellets of drug and KBr (1:10) were prepared using hydraulic press and 
analyzed in F.T.I.R spectrophotometer. Drug –Excipient Incompatibility studies were 
carried out to detect the incompatibility between API and Excipients such that drug 
stability can be predicted at storage conditions. The studies were carried by different 
methods used, F.T.I.R spectra interpretation gives the picture about the incompatibility 
between drug and excipient. 
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RESULT AND DISCUSSION 
Preformulation Studies: 
Physical Characterization: 
Cefixime: 
 
 
 
 
 
Table:11 Physical Characterization of Cefixime 
Melting Point Determination: 
Drug Reported Melting Point Observed Melting Point 
Cefixime 205 – 2070C 205.80C 
 
Table: 12 Melting point determination of the Cefixime 
Conclusion: the drug melting point range in value. 
Solubility: 
 The solubility was checked in different mediums for Cefixime which was a Class 
ІІ drug it was found to be insoluble in water and the solubility decreased with increasing 
pH . 
The solubility of the cefixime as followed; 
0.1N HCl< pH 4.5 Acetate Buffer <  pH 6.8 < pH 7.4 Phosphate buffer 
Conclusion: The appropriate medium for the  drug was found to be pH 0.1 Hcl. So it was 
used as the dissolution medium for the further evaluation. 
Color Whitish 
Odour Odour less 
Appearance Powder 
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Density and Flow Properties: 
 
 
 
 
 
 
Table:13 Flow properties of  Cefixime 
Conclusion: The  drug having poor flow property. 
F.T.I.R of The Drug And Excipients: 
F.T.I.R OF CEFIXIME 
3740  
 
Fig.6 
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DRUG+EUDRAGIT 
 
Fig.7 
DRUG+LACTOSE 
 
Fig.8 
 
 
 
 C:\OPUS_7.0.122\MEAS\DRUG+LACTOSE.0          
DRUG+LACTOSE            
3898.
07 
3728.
36 
3668.
76 
3643.
93 
3522.
79 
3329.
96 
3259.
40 
2977.
94 
2897.
24 
2350.
17 
2312.
36 
1649.
04 
1511.
89 
1421.
22 
1383.
07 
1361.
22 
1338.
69 
1257.
90 
1200.
2  
1166.
14 
1138.
03 
1115.
37 
1090.
19 
1069.
13 
986.3
8 
898.1
5 
874.4
8 
752.2
3 
670.3
6 
629.0
1 
601.3
6 
100
0 
150
0 
200
0 
250
0 
300
0 
350
0 Wavenumber 
cm-1 
8
0 
8
5 
9
0 
9
5 
Transmittance 
[%] 
 
 C:\OPUS_7.0.122\MEAS\DRUG+EUDRAGIT.0          
DRUG+EUDRAGIT            
3728.3
2 
3643.5
9 
3439.8
3 
2977.0
2 
2887.5
3 
2833.1
6 
2350.2
1 
2312.0
9 
1639.0
4 1451.9
2 1374.6
7 
1048.9
7 
942.6
4 
10001500200025003000 3500
Wavenumber cm-1 
75
80
85 
90 
Transmittance [%] 
 
                                                                Result and Discussion  
 
Department of pharmaceutics, Cherraan’s College of Pharmacy, Coimbatore. 74 
 
3728.62
3440.00
2956.92
2916.74
2849.77
2349.57
2311.47
1638.49
1574.39
1537.53
1464.75
1419.24 1112.67
1063.56
948.35876.42
719.80
664.26612.38 
570.25
100015002000 2500 30003500
Wavenumber cm-1
70
75
80
85 
90 
95 
Transmittance [%] 
DRUG+CARBOPOL                            
 
 
DRUG+MG.STERATEFfi 
 
 C:\OPUS_7.0.122\MEAS\CARBOPOL+DRUG.0          
CARBOPOL+DRUG            
3726.9
9 
3666.9
5 
3642.8
5 
3439.9
8 2976.6
8 
2887.8
5 
2833.8
8 
2312.9
2 
1645.7
2 
1453.0
0 1374.8
8 
1314.6
4 
1049.6
0 
943.5
5 
10001500200
0 
25003000350
0 Wavenumber cm-1
7
5 
8
0 
85
90
Transmittance [%]
 
Fig.9 
Fig.10 
                                                                Result and Discussion  
 
Department of pharmaceutics, Cherraan’s College of Pharmacy, Coimbatore. 75 
 
DRUG+HPMC
 
 
                              DRUG+SODIUM BICARBONATE 
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TALC+DRUG 
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Conclusion: There is noappearance or disappearance of characteristic peaks in above 
spectrum . 
Evaluation Of Formulated Blend: 
 
 
 
 
 
 
 
 
 
 
 
 
Table:  Evaluations of the Formulation Blend 
Conclusion: The formulation blend was good flow property. 
 
 
 
 
 
 
 
 
Batch 
code 
Bulk 
density 
gm/cc 
Tapped 
density 
gm/c.c 
 
Carr’s 
index 
% 
Hausner 
ratio 
Angle of 
repose 
θ 
F1 0.5208 0.6250 16.666 1.2000 21.32 
F2 0.5434 0.6250 13.0434 1.1500 23.51 
F3 0.5434 0.6250 13.0434 1.1500 23.14 
F4 0.5208 0.5682 8.3333 1.0909 21.24 
F5 0.5952 0.6579 9.5238 1.1052 21.26 
F6 0.5952 0.6579 9.5238 1.1052 21.65 
F7 0.5208 0.6579 20.833 1.2631 21.75 
F8 0.5952 0.6944 14.2857 1.1666 22.42 
F9 0.5952 0.6944 14.2857 1.1666 22.55 
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Evaluation of Cefixime Matrix Tablet: 
 
 
Table:14 Evaluations of the Cefixime Matrix Tablet 
Conclusion: The weight variation of each formulation not out of limit ±7.5, Hardness 
of the formulation is studied and values are not less than 5 kg/cm2 limits. Friability  is not 
more than 1% of the original weight and disintegration also studied. 
 
 
 
 
 
 
Batch 
code 
Average 
Weight 
mg 
Thickness 
mm 
Diameter 
mm 
Hardness 
Kg/c.m 
Friability 
% 
Drug 
content 
% 
Swelling 
index 
% 
F1 503.55 4.13 12.16 7.0 0.51 97.15 92.05 
F2 505.33 4.15 12.10 7.1 0.55 96.12 94.06 
F3 506.43 4.19 12.11 7.3 0.45 97.03 98.02 
F4 507.51 4.10 12.13 6.8 0.47 95.21 94.22 
F5 501.37 4.12 12.05 6.9 0.60 96.36 95.55 
F6 502.21 4.11 12.12 6.9 0.47 95.01 92.05 
F7 501.05 4.14 12.10 7.5 0.62 97.36 93.45 
F8 500.00 4.05 12.12 7.2 0.26 97.21 97.35 
F9 498.83 4.20 12.14 7.4 0.65 96.25 98.25 
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Photos of Formulation F-3&F-5: 
 
FIG-:  photo of F-3 formulation 
 
FIG-:  photo of F-5 Formulation 
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 In-Vitro Drug Release : 
Standard Calibration Curve Of Drug: 
Calibration Curve values of Cefixime: 
S.No Concentration(µg/ml) Absorbance 
1 50 0.312 
2 75 0.458 
3 100 0.625 
4 125 0.781 
5 150 0.937 
 
Table:15 Calibration curve values of Cefixime 
Standard Graph of Cefixime: 
 
 
 
FIG: 16 Standard graph of Cefixime 
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Dissolution Profile Of CefiximeTablet: 
Apparatus: USP- type (6-paddle) 
Medium    :  pH0.1N Hcl buffer 
Rpm       : 50 rpm 
Volume     : 900ml(1000ml-100ml) 
Absorption maxima: 235nm 
In-Vitro Drug Release: 
% Cumulative Drug Release: 
% Cumulative Drug Released(C.D.R)   
Time(hr) F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9 
0 0 0 0 0 0 0 0 0 0 
2 40.25 55.23 37.52 42.89 39.05 23.56 35.06 28.25 23.25 
4 55.27 60.25 46.49 48.32 50.99 35.96 40.25 35.62 33.62 
8 66.25 65.54 52.49 55.65 55.144 50.25 42.65 40.25 52.25 
16 75.28 85.62 64.82 67.89 67.47 65.23 55.98 52.36 55.95 
20 90.25 89.85 74.56 87.32 78.33 72.35 58.61 56.25 56.28 
24 92.55 94.32 96.96 90.41 97.06 80.45 71.12 60.21 79.28 
Table no-29: % C.D.R of F-1 to F-9  
FormulationsFIG-24: %C.D.R of F-1 to F-9 
Formulations
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Swelling Index of the F-3&F-5 Formulations: 
S.No Time in hours F-3% F-5% 
1 0 0 0 
2 2 35 36 
3 4 40 45 
4 8 50 55 
5 16 74 85 
6 20 85 90 
7 24 96 94 
 
Table:15 Swelling properties of the F-3 & F-5 Formulations 
 
 
 
FIG-:16  Swelling property of F-3 & F-5 Formulations 
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Photo Graphs Of S.I Of F-3&F-5: 
 
FIG-:  Photo of F-5 before S.I 
 
FIG-:  Photo of F-3 at 24th hour of S.I 
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FIG-:  Photo of F-5 before S.I 
 
FIG-:  photo of F-5 at 24th hour of S.I 
Assay of F-3&F-5 Formulations: 
Assay(%) Formulation -3 Formulation-5 
Value 96.96% 97.06% 
 
Table:   Assay of F-3& F- 
Conclusion: The assay value is within limits only. 
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Releaseof Kinetics: 
Release Kinetics of F-3 Formulation: 
 
S.No Time SQRT Log time %C.D.R Log 
%C.D.R 
SQR of 
%C.D.R 
1 0 0 0 0 0 0 
2 2 1.41 0.30 37.52 1.5742 6.1253 
3 4 2.00 0.60 49.49 1.6673 6.8183 
4 8 2.45 0.90 52.49 1.72 7.245 
5 16 2.83 1.20 64.82 1.8117 8.0510 
6 20 3.16 1.30 74.56 1.8725 8.6348 
7 24 3.46 1.38 96.96 1.9865 9.8468 
 
Table:  Release Kinetics of 
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Conclusion: 
 In Formulation-3, the R2 values of Zero order and First order showing equal and the 
values are more than Higuchi and Korsmeyerpeppas values. 
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Stability Study: 
Result of stability conducted of  F-3 , Sample at 25°C±2°C 60%±5%RH & 
40°C±2°C 75%±5% RH  storage condition 
Product: F-3 (CEFIXIME Matrix Tablet-500mg) 
 
At25°C±2°C 60%±5%RH storage condition: 
 
Table:  Stability studies of F-3 at 25°C±2°C and 60%±5%RH   storage condition 
 
 
 
 
Parameters 
 
 
Initial 
values 
One month Two 
months 
Three 
months 
Appearance 
 
Light 
brownish-
white colour 
Light 
brownish-
white colour 
Light 
brownish-
white colour 
Light 
brownish-
white colour 
Thickness (mm) 
 
4.13 4.13 4.13 4.13 
Hardness (kg/ cm2) 
 
7.3 7.3 7.3 7.4 
Friability (%) 
 
0.4 0.4 0.4 0.4 
Dissolution test 
in hours 
(2,4,8,16,20,24hr) 
 
2-37.52% 
4-49.49% 
8-52.49% 
16-64.82% 
20-74.56% 
24-96.96% 
2-35.52% 
4-46.25% 
8-50.25% 
16-64.32% 
20-72.51% 
24-93.25% 
2-32.25% 
4-42.25% 
8-48.25% 
16-62.36% 
20-70.21% 
24-92.25% 
2-30.25% 
4-40.25% 
8-41..25% 
16-61.25% 
20-69.21% 
24-92.25% 
Assay (%) 97.80 96.89 96.50 95.50 
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 At 40°C±2°C and  75%±5% RH  storage condition: 
 
 
Table :  Stability studies of F-3 at 40°C±2°C and 75%±5% RH storage condition 
 
 
 
 
 
 
 
Parameters 
 
 
Initial 
values 
One month Two 
months 
Three 
months 
Appearance 
 
Light 
brownish-
white colour 
Light 
brownish-
white colour 
Light 
brownish-
white colour 
Light 
brownish-
white colour 
Thickness (mm) 
 
3.2 3.2 3.2 3.2 
Hardness (kg/ cm2) 
 
7.3 7.3 7.3 7.4 
Friability (%) 
 
0.4 0.4 0.4 0.4 
Dissolution test in 
hours(2,4,8,16,20,2
4hr) 
 
2-37.52% 
4-49.49% 
8-52.49% 
16-64.82% 
20-74.56% 
24-96.96% 
2-35.52% 
4-46.25% 
8-50.25% 
16-64.32% 
20-72.51% 
24-93.25% 
2-32.25% 
4-42.25% 
8-48.25% 
16-62.36% 
20-70.21% 
24-92.25% 
2-30.25% 
4-40.25% 
8-41..25% 
16-61.25% 
20-69.21% 
24-92.25% 
Assay (%) 97.80 97.67 97.03 97.45 
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Product: F-5(CEFIXIME Matrix Tablet-10mg) 
At25°C±2°C 60%±5%RH  storage condition: 
 
 
Table:  Stability studies of F-5at 25°C±2°C and  60%±5%RH  storage condition 
 
 
Parameters 
 
 
Initial 
values 
One 
month 
Two 
months 
Three 
months 
Appearance 
 
Light 
brownish-
white colour 
Light 
brownish-
white 
colour 
Light 
brownish-
white colour 
Light 
brownish-
white colour 
Thickness (mm) 
 
4.13 4.13 4.13 4.13 
Hardness (kg/ cm2) 
 
7.3 7.3 7.3 7.3 
Friability (%) 
 
0.4 0.4 0.4 0.4 
Dissolution test in 
hours(2,4,8,16,20,24hr) 
 
2-37.52% 
4-49.49% 
8-52.49% 
16-64.82% 
20-74.56% 
24-96.96% 
2-35.62% 
4-46.25% 
8-50.25% 
16-62.26% 
20-73.25% 
24-95.26% 
2-31.12% 
4-42.25% 
8-49.25% 
16-60.21% 
20-72.24% 
24-93.36% 
2-30.21% 
4-40.21% 
8-48.25% 
16-69.65% 
20-72.21% 
24-93.20% 
Assay (%) 96.4 96.4 95.6 96.1 
                                                                Result and Discussion  
 
Department of pharmaceutics, Cherraan’s College of Pharmacy, Coimbatore. 91 
 
 At 40°C±2°C 75%±5% RH  storage condition: 
 
Table:  stability studies of  F-5 at 40°C±2°C and 75%±5% RH  storage condition 
 
 
 
 
 
 
 
Parameters 
 
 
Initial 
values 
One 
month 
Two 
months 
Three 
months 
Appearance 
 
Light 
brownish-
white colour 
Light 
brownish-
white 
colour 
Light 
brownish-
white colour 
Light 
brownish-
white colour 
Thickness (mm) 
 
4.13 4.13 4.13 4.13 
Hardness (kg/ cm2) 
 
7.3 7.3 7.3 7.3 
Friability (%) 
 
0.4 0.4 0.4 0.4 
Dissolution test in 
hours(2,4,8,16,20,24hr) 
 
2-37.52% 
4-49.49% 
8-52.49% 
16-64.82% 
20-74.56% 
24-96.96% 
2-35.62% 
4-46.25% 
8-50.25% 
16-62.26% 
20-72.25% 
24-95.26% 
2-31.12% 
4-42.25% 
8-49.25% 
16-60.21% 
20-71.24% 
24-93.36% 
2-30.21% 
4-40.21% 
8-48.25% 
16-69.65% 
20-70.21% 
24-93.20% 
Assay (%) 97.4 96.21 96.6 95.1 
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DISCUSSION 
Buoyant drug delivery systems have a bulk density lower than gastric fluids and thus 
remain buoyant in the stomach for a prolonged period of time, without affecting the 
gastric emptying rate. While the system is floating on the gastric contents, the drug is 
released slowly at a desired rate from the system. After the release of the drug, the 
residual system is emptied from the stomach. This results in an increase in the GRT and a 
better control of fluctuations in the plasma drug concentrations. 
In the present work efforts have been made to develop Floating drug delivery 
system for Cefixime containing HPMC of viscosity grade (HPMC K100M) and Lactose 
CarbopolEudragit. 
The FTIR spectral analysis showed that there was no appearance or disappearance 
of any characteristic peaks of pure drug Cefixime in the physical mixture of drug and 
polymer, which confirms the absence of chemical interaction between drug and polymers. 
all formulation were evaluated for angle of repose, loose bulk density, tapped bulk 
density, compressibility index and drug content. The angle of repose value ranged from 
21o 14” ± 0.15 to 230 51” ±0.19. The results were found to be below 300 and hence the 
blend was found to have poor flow ability. Bulk and tapped densities are used for the 
measurement of Compressibility index. The LBD and TBD ranged from 0.44±0.04 to 
0.51±0.04 and 0.50 ± 0.07 to 0.59 ± 0.04respectively. The compressibility index (%) was 
then calculated form the LBD and TBD and it ranged from 8.33±0.6 to 14.28±0.8 . The 
blend was found to have free flowing property as the result were found to be below 19%. 
The Hausner ratio ranged from 1.11±0.04 to 1.18±0.08. The result indicates the free 
flowing properties of the Powder as the value was below 1.2. 
                                                                Result and Discussion  
 
Department of pharmaceutics, Cherraan’s College of Pharmacy, Coimbatore. 93 
 
The floating tablets of Cefixime were prepared by effervescent technique using 
HPMC grade of viscosity (HPMC K100M), sodium bicarbonate and citric acid, Lactose, 
Carbopol, Eudragit to. The magnesium stearate and talc were used as lubricant and 
glidant, respectively. The tablets of all formulation were subjected to various evaluation 
parameters such as thickness, diameter, weight variation, hardness, friability, drug 
content, in-vitro buoyancy lag time, total floating time, tablets density, swelling index and 
in-vitro dissolution study. 
The results of all these tests were found to be satisfactory. The thickness of the 
tablets was uniform in all formulations and ranged from 5.16±0.054mm to 5.5±0.018mm. 
The hardness of tablets in all batches ranged from 4.0±0.45 to 6.4±0 . All the 
formulations (F1-F9) passed weight variation test as per the Pharmacopoeial limit of 
±5%. The percentage friability of all batches ranged from 0.37 to 0.72 %, which was well 
below the pharmacopeial limit of 1 %. Drug content was also found to be uniform among 
the all formulations and ranged from 98.91+ 0.35% to 99.94+ 0.19 %. 
There has been considerable interest in using different Types of polymers 
controlled release drug delivery system due to their hydrophilic nature and fast hydration. 
It has been reported that polymers of different viscosity grades can yield different drug 
absorption. 
To know the kinetic drug release, the data was treated according to different 
model. The drug release data of F1-F9 fitted to Higuchi plots were best fit into Higuchi 
equation and diffusion mechanism. The diffusion is related to the transport of drug from 
the dosage form into in-vitro fluid depending upon concentration of the gradient varies 
the drug release the distance for diffusion increases. 
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In the present study in-vitro release profile could be expressed by Higuchi for all 
formulation showed good linearity indicates that diffusion is dominant mechanism of 
drug release with these formulations. 
The performance of floating formulation has been reported to be greatly affected 
by physiological conditions such as food, transport, gastrointestinal motility and so on. 
In- vitro dissolution studies of all the formulations of floating tablets of Cefixime were  
carried out in 0.1NHcl. The study was performed for 24 hours and cumulative drug 
release was calculated at every   hour time interval. In- vitro dissolution studies of all the 
formulations are shown. Three different polymers and their combination were used to 
prepare floating tablets. It was observed that the type of polymer influences the drug 
release pattern. Al the formulations contain equal amount of gas generating agent 
(Sodium Bicarbonate) and Citric Acid. 
Drug release from F3 is high due to high permeabilty. Although combination of 
significantly release the drug as compared with F3. As expected drug release depend upon 
viscosity grade and concentration of polymer used. Tablet containing Lactose,Carbopol 
(F3) showed better drug release upto 24hours. As Carbopol has greater tendency to water, 
it can  sustain the drug for 24 hours. 
 Polymeric system with low viscosity polymer (HPMC K100M) yielded a faster 
initial burst effect. Dortunc and Gunal (1997) has reported that increased viscosity 
resulted in a corresponding decrease in the drug release. Wan et al. reported similar 
results, in which they have demonstrated that HPMC with higher viscosity resulted in 
thicker gel layer formation. Once the gel layer of polymeric system is formed, there 
appears to be no difference in release rate from delivery system. 
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From results of in- vitrodrug release studies using USPXXIII dissolution 
apparatus, it concludes that F3 had better-sustained release than the other formulation (F1, 
F2, F4, F5, F6, F7,F8& F9). 
In order to understand the complex mechanism of drug release from the floating 
tablets, the in- vitroCefixime release data were fitted to Korsmeyer-peppa’s release model 
and interpretation of release exponent values (n) enlightens us in understanding the 
release mechanism from the dosage form. The release exponent values thus obtained were 
from 2.471to 2.7586. Based on these values we can say that the formulations F1 to F9 
exhibited Case II transport. 
The drug release was diffusion controlled as the plot of Higuchi’s model was 
found to be linear (r>0.9230). All formulations F3 values for zero order plot indicating 
that drug release followed zero order kinetics and drug release from these floating tablets 
were by both diffusion and erosion. 
 
 
 
 
 
 
. 
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SUMMARY AND CONCLUSION 
 The aim of study was the“Formulation and Evaluations of Cefixime Floating 
Matrix tablet using different type of polymers” having Controlled release Cefixime 
Matrix system. 
 In this,The main objective of the study was to develop a stable product which 
provides controlled drug release profiles. The optimum Formulation of F-3was given the 
best Preformulation studies and post compression studies such as Angle of repose, 
compressibility index, and thickness, hardness, content uniformity, drug release.The 
Matrix tablets were subjected to test for accelerated stability (25°C±2°Cat 60%±5% RH 
& 40°C±2°C at 75%±5% RH for 3months) studies. 
 The release kinetics profile had also given a best result. the optimum Formulation  
of F-3drug was following mixed-order kinetics . 
 In this formulation, The combination of Lactose and Carbopol wasimproved the % 
cumulative release of the drug. This was given the best release of drug within the limits 
tablet up to 20th hrs. (94.09%), ourformulation had given a good  drug releaseup to 24th 
hour(96.96%). The swelling behaviour is also within the limits only. 
 So, our formulation had produceda best result using theLactose and Carbopol 
combination in Formulation F-3. 
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